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Abstract 
Trans fatty acids, HDL-cholesterol and cardiovascular disease risk: 
Effects of dietary changes on vascular reactivity 
PhD thesis by Nicole M de Roos, Division of Human Nutrition and Epidemiology, 
Wageningen University, The Netherlands 
Intake of trans fatty acids increases the risk of coronary heart disease, even more so than 
saturated fatty acids. We wanted to investigate whether this higher risk was caused by 
the decrease in serum HDL-cholesterol by trans fatty acids. To do this, we studied the 
effect of diet-induced changes in HDL-cholesterol on vascular reactivity, a surrogate 
endpoint for coronary heart disease. Vascular reactivity was measured as flow-mediated 
vasodilation: the percentage increase in arterial diameter after a provoked increase in 
blood flow. The extent of flow-mediated vasodilation appears to be predictive of future 
coronary heart disease. The studies were performed in healthy men and women. 
Replacement of 9.2% of energy (en%) from saturated fatty acids by trans fatty acids 
lowered serum HDL-cholesterol after 4 weeks by 0.39 (95%CI 0.28, 0.50) mmol/L and 
impaired flow-mediated vasodilation from 6.2% to 4.4%, a decrease of 1.8%-points 
(0.4, 3.2). The activity of serum paraoxonase, an HDL-bound esterase which might 
protect against atherosclerosis, decreased by 6% (2%, 10%). We then verified whether a 
different HDL-lowering diet also impaired flow-mediated vasodilation. In this study, we 
replaced «20en% monounsaturated fatty acids with carbohydrates: HDL-cholesterol 
decreased by 0.21 (0.17, 0.26) mmol/L and flow-mediated vasodilation increased from 
4.1% to 4.8%, an increase of 0.7% (-0.6,1.9). This result did not support our hypothesis 
that decreases in HDL-cholesterol increase risk of cardiovascular disease; however, the 
decrease might have been too small to cause an effect. We therefore investigated in an 
oral fat-loading test whether trans fatty acids could impair flow-mediated vasodilation 
while HDL-cholesterol was constant. This was not the case; flow-mediated vasodilation 
after an oral fat load of lg/kg bodyweight was 3.1% versus 2.6% before, and trans fatty 
acids and saturated fatty acids had similar effects. Serum paraoxonase activity parallelled 
the change in flow-mediated vasodilation, and was slightly increased after an oral fat 
load with either trans or saturated fatty acids. 
We conclude that replacement of saturated fatty acids by trans fatty acids impairs 
vascular function within 4 weeks. This may explain why trans fatty acids relate more 
strongly to risk of cardiovascular disease than saturated fatty acids. Whether the effects 
on vascular function are caused by changes in HDL-cholesterol remains to be resolved. 
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General Introduction 
C H A P T E R 1 
Rationale for the studies in this thesis 
The average diet of a Dutch adult contains lOOg of fat1. A small part, 2-5% of total fat, is formed 
by trans fatty acids; unsaturated fatty acids with one or two double bonds in the trans 
configuration. The main source of trans fatty acids - or trans fats - are partially hydrogenated 
vegetable oils that are formed when liquid oils are hardened to produce shortenings, frying fats, 
and other solid fats. A smaller amount of trans fat is derived from meat or dairy products of 
ruminant animals, such as cows, sheep, and goats. 
A high intake of trans fat increases the risk of coronary heart disease2, and some investigators 
believe that their effect is stronger than that of saturated fatty acids. This difference in risk 
cannot be explained by differences in effect on LDL-cholesterol, because both types of fatty 
acids increase LDL-cholesterol to a similar extent However, trans fatty acids decrease serum 
HDL-cholesterol when they replace saturated fatty acids, and a low HDL-cholesterol is 
associated with increased risk of cardiovascular disease. We postulated that if trans fats have 
indeed a stronger effect than saturated fatty acids on risk of cardiovascular disease, this would be 
caused by differences in effect on HDL-cholesterol. The underlying question of the studies in 
this thesis therefore was: 
Does the decrease in serum HDL-cholesterol by trans fatty acids explain their 
stronger effect on cardiovascular disease as compared to saturated fatty 
acids? 
We have not answered this question directly. Instead, we studied effects of trans fatty acids and 
of changes in HDL-cholesterol on a surrogate endpoint of cardiovascular disease: flow-mediated 
vasodilation. Thus, our research question was whether a decrease in HDL-cholesterol or a high 
intake of trans fatty acids impaired flow-mediated vasodilation. 
Flow-mediated vasodilation is the widening of arteries in response to increased blood flow3. 
It is a measure of integrity and function of the vascular endothelium4. We used this marker 
because it appears to be predictive of future cardiovascular events; it correlates with known risk 
factors for cardiovascular disease; it quickly responds to treatment; and it can be used in a non-
medical setting. All studies were performed in healthy volunteers. 
In the following paragraphs the relation between trans fatty acids, HDL-cholesterol, and 
coronary heart disease will be discussed. 
Sources of trans fatty acids 
The majority of trans fats in western-type diets are the partially hydrogenated vegetable and 
marine oils5. Their contribution to trans fat intake in the Netherlands is «80%5>6. Main sources of 
partially hydrogenated oils are fats (frying and cooking fats, solid margarines and spreads), baked 
goods (biscuits, cakes, buns), chips, trench fries, and savoury snacks5. 
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The most common trans fatty acids in partially hydrogenated vegetable oils are the trans isomers 
of the monounsaturated octadecenoic acid (C18:l)5. They include elaidic acid, which is the trans 
isomer of oleic acid (or-C18:ln-9). In contrast, partially hydrogenated marine oils contain mainly 
trans fatty acids with 20-22 carbon atoms. 
Figure 1.1: 
Chemical structure of 
c/s-C18:1n-9 (oleic acid) 
and fra/?s-C18:1n-9 
(elaidic acid) 
Cis double bond: oleic acid 
Trans double bond: elaidic acid 
The remainder of trans fat is largely derived from ruminant animal sources; they contribute 
«20% of total trans fat intake in the Netherlands5,6. Main sources are meat and meat products, 
cheese, and milk. Milk fats mainly contain vaccenic acid (C18:ln-7) and its positional isomers7. 
An additional small amount of trans fat is found in liquid vegetable oils; they are formed during 
the process of deodorisation of the oils and contain mainly />w»x-polyunsaturated fatty acids such 
as #a«.f-alpha-linolenic acid (C18:3n-3)8. Intake of /ta«.r-alpha-linolenic acid is estimated to be 20-
600 mg/d in European countries9. 
The intake of partially hydrogenated vegetable oils has decreased from 4.3% of energy (en%) 
in 1985 to 1.5 en% in 1995 in the Netherlands. In contrast, the intake of trans fats from ruminant 
animal sources has been stable at about 0.7en%6. Reports on the adverse effects of trans fats led 
food manufacturers to remove them from margarines for the consumer market10. Margarines 
for the catering industry, shortenings for bakers, and frying fats for fast food restaurants, 
however, still contain considerable amounts of trans fats. The reason is that hydrogenated oils 
add firmness and texture to products and can therefore not always be replaced by oils in their 
natural fluid state. Another advantage of hydrogenation is that it makes oils less susceptible to 
oxidation (spoilage) and therefore more stable upon deep fat frying. Replacement of partially 
hydrogenated vegetable oils by solid tropical fats is a technical possibility, but these fats are rich 
in saturated fatty acids and therefore undesirable from a public health view. 
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Trans fatty acids and coronary heart disease risk 
Our knowledge on health effects of trans fats is based on observational and experimental diet 
studies. The strength of most observational studies is their endpoint coronary heart disease, 
often in the form of fatal or non-fatal myocardial infarction or stroke. Their weaknesses include 
errors in estimating trans fatty acid intake and the limited possibilities to correct for confounding 
variables, such as saturated fat intake and a sedentary lifestyle. 
These weaknesses can be eliminated in experimental diet studies: the intake of dietary 
components can be controlled, and randomising volunteers to treatment or control group 
eliminates bias due to e.g. lifestyle factors. However, a weakness of diet studies is their 
limited length and number of volunteers which makes it impractical to study effects on 'hard' 
coronary heart disease endpoints. Instead, effects on risk markers such as serum cholesterol 
have been studied. 
observational studies 
prospective observational follow-up studies 
Four large prospective observational follow-up studies have estimated the effects of intake of 
trans fats on risk of coronary heart disease (Table 1.1). In the only study with women, the Nurses' 
Health Study11, over 80,000 nurses were followed-up for 14 years; 939 coronary events were 
recorded in this period. Their mean intake of trans fats at baseline, estimated with food frequency 
questionnaires, was 2.2% of energy. The relative risk of coronary heart disease, in a multivariate 
model, was 1.62 (95% CI, 1.23 to 2.13) for each increase of 2% of energy from trans fats. A 
smaller effect was seen in the Health Professionals follow-up study12. During a 6-year follow-up 
of nearly 44,000 men, 734 coronary events - including 229 coronary deaths - were recorded. 
Median intake of trans fats ranged from 1.5 g/d in the lowest quintile to 4.3 g /d in the highest 
quintile of intake; the relative risk of coronary heart disease was 1.13 (95% CI, 0.81 to 1.58) for 
each additional 2% of energy from trans fats. A comparable effect was seen in the Alpha-
Tocopherol Beta-Carotene Cancer Prevention Study that was performed in Finland13. In this 
study, nearly 22,000 smoking men were followed-up for 6.1 years; 2034 coronary events -
including 635 coronary deaths - were recorded. Median intakes of trans fats were slightly higher 
in this Finnish population than in the US Health Professionals, and ranged from 1.3 g/d in the 
lowest quintile to 6.2 g /d in the highest. The relative risk for each increase in trans fatty acid 
intake by 2% of energy was 1.14 (95% CI, 0.96 to 1.35). The Dutch Zutphen Elderly Study 
confirmed the positive association between trans fatty acid intake and risk of coronary heart 
disease. In this study 667 men with a mean trans fatty acid intake of 4.3% of energy at baseline 
were studied prospectively 6. After 10 years of follow-up 98 coronary events had been recorded; 
the relative risk of coronary heart disease for each increase in trans fatty acid intake by 2% of 
energy was 1.28 (95% CI, 1.01 to 1.61). Oomen et al pooled the data of these four prospective 
studies and estimated that each 2% increase in energy intake from trans fats increased risk of 
cardiovascular disease by 25%6. 
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Table 1.1 Relative risks of coronary heart disease for each additional 2% of energy from 
trans fatty acids in 4 prospective cohorts 
study number of follow-up (y) number of events relative risk (95% 
subjects CI) 
939 1.62 (1.23 to 2.13) 
734 1.13(0.81 to 1.58) 
2034 1.14 (0.96 to 1.35) 
Nurses' Health 
Study 
Health 
Professionals 
Alpha-
Tocopherol Beta-
Carotene Cancer 
Prevention Study 
Zutphen Elderly 
Study 
80,082 women 
43,757 men 
21,930 men 
667 men 
14 
6 
6.1 
10 98 1.28(1.01 to 1.61) 
Data on effects of the different sources of trans fats are limited. It is known, however, that 
dietary fatty acids with small differences in structure may have large differences in effect, and 
therefore we cannot assume that all trans fats will act identically8. In the Dutch Zutphen Elderly 
Study; the effects of trans fats from animal origin appeared to be similar to those of partially 
hydrogenated fats6. In the Nurses' Health Study, however, trans fats from ruminant animal fats 
appeared to be inversely related to risk, while trans fats from vegetable fats increased risk of 
coronary heart disease14. In this study, margarine, beef, pork, or lamb as a main dish, and cookies 
and white bread contributed most to trans fatty acid intake. Of these products, margarine, 
cookies and white bread had positive associations with risk while the meat sources had not, 
indicating that only the trans fats from partially hydrogenated vegetable oils increased risk of 
coronary heart disease. In the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study the 
risk associated with trans fat intake was largely attributable to elaidic acid intake from partially 
hydrogenated fat, and not to trans fats from animal sources. 
Case-control studies 
Another approach to investigating whether trans fats are related to coronary heart disease is to 
compare trans fat intake across patients and healthy controls in a case-control study. Ascherio et 
al compared 239 men and women who were admitted to hospital for a first myocardial 
infarction with 282 population controls. Intake of trans fats was 4.36 g/d or 1.6% of energy in 
men and 3.61 g/d or 1.7% of energy in women; hydrogenated fats contributed 74% of the total 
trans fat intake. Control subjects had a lower intake of trans fats than patients: 3.78 g/d versus 
4.68 g/d (P for difference <0.001). The relative risk of myocardial infarction after adjustment for 
known risk factors, other fats, and cholesterol intake, was 2.03 (95% CI, 0.98 to 4.22) for the 
highest versus the lowest quintile of trans fat intake15. Plasma concentrations of LDL- and HDL-
cholesterol had been measured in 458 patients and controls, and the investigators evaluated 
whether the association between trans fat intake and myocardial infarction was mediated by these 
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risk factors. The relative risk of myocardial infarction among these subjects, comparing the 
highest versus the lowest quintile of trans fat intake, was 2.23 (95% CI, 1.19 to 4.18) before 
adjustment for plasma LDL- and HDL-cholesteroL and 2.12 (95% CI, 1.09 to 4.11) after 
adjustment Thus, a higher trans fat intake appeared to increase risk of myocardial infarction 
independent of its effects on lipoproteins. 
No such clear relation between trans fat intake and myocardial infarction was seen in the 
European multicentre EURAMIC study16. In this study, trans fatty acid content of adipose tissue 
of 671 men with a first myocardial infarction was compared with that of 717 age-matched 
controls without a history of myocardial infarction. The C18 trans fatty acid content of adipose 
tissue was used as a biomarker of trans fat intake, and was shown to be 1.60% in patients and 
1.59% in controls, with a difference of 0.01% (95% CI, -O.02 to 0.04). Thus, there was no 
overall difference between cases and controls. Of the ten centres that collaborated in this study, 
two were from Spain, and the men from these two centres had very low CI 8 trans fatty acid 
contents in their adipose tissue; ranging from 0.40 to 0.47%. After exclusion of these two 
centres, the second highest and the highest quintile of trans fats were associated with higher risks 
of myocardial infarction, but the relation was not significant The investigators suggested that the 
contribution of trans fats to risk of myocardial infarction might be restricted to countries with 
high trans fat intakes. A comparable study in the UK, with 66 men who had died from sudden 
cardiac arrest and 286 healthy controls, showed no relation between adipose tissue CI 8:1 or 
CI 8:2 trans fats and cardiac death17. This study was apparently too small to detect any difference 
between cases and controls; the confidence intervals were wide, and diabetes, an established risk 
factor for coronary heart disease, was not associated with events. 
Thus, the relation between trans fat intake and risk of myocardial infarction or cardiac death is 
inconsistent in these case-control studies. However, this may have been due to lack of power in 
some of the studies. 
Cross-sectional studies 
Only one cross-sectional study of trans fat intake and coronary heart disease in western 
subjects was found18. The study was conducted in 10,359 Scottish men and women, who were 
divided in three groups: those who reported prevalent coronary heart disease (369 men and 235 
women), those with symptoms of coronary heart disease that had not been diagnosed previously 
(659 men and 795 women), and those who were free of symptoms and who did not use anti-
hypertensive, cholesterol-lowering or other drugs related to coronary heart disease (3720 men 
and 3749 women). Intake of trans fats had no clear effect on the risk of coronary heart disease, 
neither in the patients with prevalent coronary heart disease nor in the symptomatic but 
undiagnosed subjects. The intake of trans fats was high and ranged from 3.8 g/d in the lowest 
quintile to 11.9 g/d in the highest quintile for men, and from 3.1 to 11.0 g/d for women. About 
60% of all trans fats in the diet was derived from partially hydrogenated fats. The lack of relation 
between trans fats intake and coronary heart disease might be due to the design of this study; 
patients with coronary heart disease might have changed their dietary habits, and are likely to use 
margarines rich in polyunsaturated fats instead of trans fats. This may have obscured an existing 
relation. 
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experimental diet studies 
Serum lipoproteins 
Experimental diet studies with trans fats have focussed on their effect on serum lipoproteins, 
especially since Mensink and Katan showed that these fats differ from saturated fats in their 
effects on serum HDL-cholesterol19. When data of controlled diet studies are combined, it can 
be estimated that replacement of 1% of energy from carbohydrates by trans fats increases serum 
LDL-cholesterol by 0.034 mmol/L and decreases serum HDL-cholesterol by 0.004 
mmol/L20-21. Such a change in cholesterol concentrations can be translated in change in risk 
according to Willett, an increase in total cholesterol of 0.5 mmol/L increases risk of coronary 
heart disease by about 25%22. Thus, each additional percent from trans fats will increase risk of 
coronary heart disease by 1-2%. This estimate is much less than the increase in risk of 25% for 
each 2% of energy from trans fats that was estimated from epidemiological studies. Thus, other 
effects appear to contribute to the risk associated with high intakes of trans fats. 
Other effects of trans fatty acids 
In addition to their effects on serum LDL- and HDL-cholesterol, trans fats have consistency 
been shown to increase serum lipoprotein(a)23"26. This particle, which is composed of an LDL 
particle attached to apolipoprotein(a), has been associated with coronary heart disease in 
epidemiological studies27. Its concentration in human serum is largerly genetically determined28 
but can be modified by diet. The increase in serum lipoprotein(a) is about 0.5 mg/dL per 2en% 
increase in trans fat intake2. This appears to be an adverse effect, but exactly how this translates 
into risk of coronary heart disease is unclear because of the complex relation between 
lipoprotein(a) with cardiovascular disease28. 
Other effects of trans fats that have been studied in human studies are blood pressure, which 
was unaffected29, and incorporation of certain trans fats in blood platelets30, which might be 
increased in patients with more severe coronary artery disease. This latter effect, however, needs 
confirmation, and the composition of platelets as a marker of disease needs to be validated. 
In conclusion, changes in serum lipoprotein concentrations only partly explain why a high 
intake of trans fats increases risk of coronary heart disease. This suggests that additional 
mechanisms are involved in the pathway between trans fat intake and coronary heart disease. 
Serum HDL-cholesterol and coronary heart disease risk 
Unlike saturated fatty acids, trans fats decrease serum HDL-cholesterol when they replace other 
fats in the diet We hypothesised that this might explain why trans fats relate more strongly to 
risk of cardiovascular disease than saturated fatty acids, because there is increasing evidence that 
HDL-cholesterol is causally related to coronary heart disease31. 
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Cross-sectional studies and prospective follow-up studies 
Several cross-sectional studies have shown that coronary heart disease is more common in men 
and women with low serum HDL-cholesterol concentrations than in those with high serum 
HDL-cholesterol32-34 Moreover, a low concentration is predictive of future cardiovascular and 
coronary events: Two papers summarised the results of six cohort studies (FHS, LRCF, CPPT, 
MRFIT, BRHS, and BIRNH)' and found risk reductions for coronary heart disease between 
1.3-4.2% for each 1 mg/dL (0.026 mmol/L) higher baseline serum HDL-cholesterol35.36. The 
effects on cardiovascular disease were somewhat smaller, but consistent across studies. The 
protective effect of HDL-cholesterol is not restricted to subjects in Europe and the United 
States but was also seen in a group of Japanese men37. 
Drug trials 
It is widely recognised that lowering serum LDL-cholesterol reduces the risk of cardiovascular 
disease with 1-2% for each percent lowering38. Several drug studies suggest a similar effect of 
increases in serum HDL-cholesterol. However, most drug trials aimed at lowering serum LDL-
cholesterol; changes in HDL-cholesterol were no priority. The only exception is the Veterans 
Affairs High-Density Lipoprotein Intervention Trial (VA-HIT), which was specifically designed 
to study effects of increasing HDL-cholesterol with gemfibrozil. In this trial, 2531 men with a 
history of coronary heart disease were randomly allocated to treatment or placebo. After a 
median follow-up of 5.1 years, the number of primary coronary events (nonfatal myocardial 
infarction or death from coronary heart disease) was 275 in the placebo group and 219 in the 
drug group39. Serum HDL-cholesterol was 6% higher and serum triglycerides 31% lower in the 
treatment group than in the placebo group after 1 year; serum LDL-cholesterol remained stable. 
The investigators calculated that a 5 mg/dL (0.13 mmol/L) increase in HDL-cholesterol 
reduced the number of coronary events by 11%; changes in HDL-cholesterol therefore 
contributed to the beneficial effect of gemfibrozil40. 
Further evidence for a protective effect of increases in serum HDL-cholesterol is derived 
from drug trials that were designed for studying effects of lowering LDL-cholesterol or 
triacylglycerols on coronary heart disease risk. These studies, typically with 1000-4000 subjects, 
report risk reductions up to 6% per mg/dL or 23% per 0.1 mmol/L41-43. 
Studies with intermediate endpoints of coronary heart disease also show a better outcome 
when HDL-cholesterol concentrations increase during the follow-up period44 or when baseline 
HDL-cholesterol concentrations are higher45. 
In summary, HDL-cholesterol shows an inverse relation with risk of coronary heart disease. 
Drugs that increase serum HDL-cholesterol reduce risk of coronary heart disease. 
1
 Framingham Heart Study, Lipid Research Clinics Follow-up study, Coronary Primary Prevention Trial, Multiple Risk Factor 
Intervention Trial, British Regional Heart Study, and Belgian Interuniversity Research on Nutrition and Health. 
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Why was flow-mediated vasodilation chosen as an outcome of the studies? 
Our aim was to investigate whether trans fats increase risk of coronary heart disease more than 
saturated fats because trans fats decrease HDL-cholesterol. Ideally we would have studied this in 
a long-term trial with hard endpoints, such as myocardial infarction, with the volunteers on 
controlled diets rich in either saturated fat or trans fat. However, even if such a study would be 
feasible - despite the huge numbers of volunteers and the long follow-up period - it would be 
unethical because we know that diets high in saturated fat increase risk of cardiovascular disease. 
Thus, we looked for a risk marker that would add new information to our knowledge of the 
effect of trans fats but would respond within weeks. Flow-mediated vasodilation appears to be 
such a marker. 
Flow-mediated vasodilation is the increase in arterial diameter that is induced by a local 
increase in arterial blood flow. Such an increase in blood flow (hyperemia) is produced by 
inflating a blood pressure cuff around the arm to occlude arterial flow for 5 min. Then, release 
of the cuff leads to hyperemia that increases the shear stress on the endothelial cells. This 
stimulates the endothelial cells to releasing nitric oxide, a potent vaodilator. The vasodilation is 
measured non-invasively with high-resolution ultrasound, a technique first described by 
Celermajer and co-workers46. The measurement depends on reproducible measurements of the 
lumen of the brachial artery (Figure 1.2). 
In our studies with healthy volunteers, 5 minutes of ischemia induced by a pressure cuff 
around the lower arm, inflated to a pressure of 240 mmHg, induced a flow-mediated 
vasodilation of 5% of the baseline diameter. 
Flow-mediated vasodilation depends on the release of nitric oxide by the endothelial cells4. If 
nitric oxide release is blocked by chemical agents, for example by N-monomethyl-L-arginine, 
flow-mediated vasodilation is abolished47. 
Figure 1.2: 
Ultrasound image of the 
brachial artery. 
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Flow-mediated vasodilation and risk of cardiovascular disease 
Flow-mediated vasodilation correlates with all known risk factors of cardiovascular disease48. 
Thus, a high serum LDL-cholesteroL, homocysteine, smoking, diabetes, hypertension, and old 
age are all associated with impaired flow-mediated vasodilation. Changes in these risk factors to 
more desirable values often improves flow-mediated vasodilation49'50. Patients with coronary 
heart disease show less flow-mediated vasodilation than healthy controls51. More important, 
however, is the comparison of flow-mediated vasodilation with validated markers of coronary 
heart disease. 
Such comparisons showed that flow-mediated vasodilation in the brachial artery correlates 
with the number of diseased coronary vessels in patients with chest pain 51-52. It also correlates 
with flow-mediated vasodilation in the coronary arteries53 and with intima media thickness of the 
common carotid artery54. Although these correlations suggest that flow-mediated vasodilation 
might be predictive of future coronary events, follow-up studies are needed to prove this. One 
study with 73 patients with chest pain showed that cardiovascular events occurred more during a 
5-year follow-up in 46 patients with an initial flow-mediated vasodilation of <10% than in 27 
other patients with a vasodilation >10%55. However, this result was biased by the fact that 
patients with low initial flow-mediated vasodilation had more severe stenosis at baseline - and 
therefore a higher risk - than patients with high flow-mediated vasodilation. In another study, 
flow-mediated vasodilation of the coronary arteries was shown to be predictive of future 
coronary events56. Up to now, these are the only reports in the literature on the predictive value 
of flow-mediated vasodilation. 
In conclusion, it is likely but not proven that changes in flow-mediated vasodilation reflect 
changes in cardiovascular disease risk. The results of the studies described in this thesis should 
therefore be balanced against the existing knowledge on the relation between trans fats, HDL-
cholesterol and coronary heart disease. 
Outline of the studies in this thesis 
Before we started the diet studies we assessed the within-subject variability of flow-mediated 
vasodilation in a group of healthy young volunteers (Chapter 2). This variability was crucial for 
our estimate of sample size in the next studies. We then performed three diet studies: two dietary 
controlled studies and one test meal study. In the two dietary controlled studies all food was 
prepared for the volunteers during two periods of 3-4 weeks. Effects on flow-mediated 
vasodilation were measured at the end of each period (Chapters 3-6). In the test meal study we 
studied changes in flow-mediated vasodilation in response to oral fat loads on 4 occasions 
(Chapter 7). The results of all studies will be combined in the final chapter (Chapter 8, General 
Discussion). 
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inflow-
mediated vasodilation of the brachial 
artery in healthy men and women 
NM de Roos, ML Bots, EG Schouten, MB Katan 
A B S T R A C T 
Background Flow-mediated vasodilation (FMD) of the brachial artery is used as a marker of 
cardiovascular disease risk. It is defined as the percentage dilation from baseline diameter in 
response to a provoked increase in blood flow. The within-subject variability, crucial in the 
design of trials with FMD as an endpoint, appears to vary widely between studies. 
Aim To assess the within-subject variability of FMD in healthy subjects and to estimate the 
number of subjects needed to detect various treatment effects in intervention trials and 
observational studies. 
Design FMD was assessed with B-mode high-resolution ultrasound. Thirteen subjects were 
measured on 6 occasions, after they had fasted overnight. 
Results The mean (±SD) FMD was 5.60±2.15% of the baseline diameter. The within-
subject standard deviation was 2.8%-points, which resulted in a coefficient of variation (CV) 
of 2.8/5.6xl00%=50.3%. The CVs for the baseline and maximum diameter were much 
smaller: 4.8% (SD 0.193 mm, mean 4.060 mm) for the baseline and 5.2% (SD 0.222 mm, 
mean 4.285 mm) for the maximum. The number of subjects needed to detect a treatment 
difference of 2%-points in FMD with a probability of 0.05 and a power of 0.90 would be 42 
in a cross-over design and 83 per group in a parallel design for comparison of group 
changes. 
Discussion The within-subject variability of FMD is large, about 50% of the mean response. 
This includes biological and technical variation. Repeated measurements and repeated 
readings of recorded measurements are recommended to reduce variability. 
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Introduction 
Non-invasive assessment of flow-mediated vasodilation (FMD) is used to evaluate endothelial 
function and is used as a surrogate endpoint for cardiovascular disease in observational and 
experimental studies. It is based on the ability of vascular endothelial cells to respond to changes 
in shear stress. The response consists of a release of nitric oxide, a potent vasodilator that relaxes 
the smooth muscle cells in the vascular wall1, resulting in an increase in lumen diameter. FMD 
can be non-invasively assessed from high-resolution ultrasound images of the brachial artery at 
baseline and at maximum dilation2. In healthy people FMD is 5-15% of the baseline diameter, 
but in patients with cardiovascular disease FMD is impaired or absent3-4. An impaired FMD 
appears to be predictive of future events: patients with chest pain and impaired FMD were 
shown to be more likely to experience cardiovascular events in a 5-year period than patients with 
preserved FMD5. 
The diameter of the brachial artery can be measured reproducibly with high-resolution 
(7.5-13 MHz) ultrasound: in the literature we found coefficients of variation (within-subject 
standard deviation divided by mean baseline diameter) of 1.5-6%. At a mean baseline diameter 
of 4.0 mm this corresponds with a within-subject standard deviation of 0.06-0.24 mm. However, 
the reported within-subject variability of the FMD is less consistent coefficients of variation 
ranging from 1.2% to 13.6% (Table 2.1) have been reported. Instead of coefficients of variation, 
some investigators report alternative measures of reproducibility, that are not well defined. 
Moreover, most reproducibility studies were based on only two repeated measurements in less 
than 10 subjects. Therefore we designed a study that would adequately estimate within-subject 
variability in FMD. We used this information to estimate sample sizes for experimental studies 
that compare treatment differences on flow-mediated vasodilation. 
Subjects and Methods 
The Medical Ethics Committee of Wageningen University approved the study protocol. We 
explained aim and design of the study to the volunteers who all signed informed consent forms. 
Number of subjects and measurements 
We wanted to estimate the within-subject variance with a certain precision, defined by the width 
of the 95% confidence interval (CI). We first determined the desired width of the 95% CI, 
which has a Chi-square distribution that becomes narrower with more degrees of freedom 
(df)6-7. The distribution is skewed: up to 40 df the confidence interval narrows markedly when 
the number of df increases but over 40 the interval narrows much slower. We chose 0.72a2-
1.48a2 as the desired width of the 95% CI, corresponding with 60 df. The number of df for a 
within-subject variance is the number of subjects times {the number of repeated 
measurement minus 1}. We decided to perform 6 repeated measurements and therefore needed 
12 subjects (I2x{6-1}=60 df). 
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Table 2.1 Measures of reproducibility of flow-mediated vasodilation of the brachial 
artery as reported in various studies 
number of 
subjects 
3 
40m/f 
8m 
15 
7m 
5 
10f 
3 m 
30m/f 
10m/f 
? 
48 
number of repeated 
measurements per 
subject 
>4 times 
4 
5 within 1 month 
2 times 
2 within 1 day 
2 times, 2 weeks 
apart 
2 on different days 
2 on different days 
2 times 
2 times on different 
days 
2 times on separate 
days 
2 times separated 
by 7 days 
reproducibility 
average CV of 13.6% 
between-scan variance 3.45; 
overall CV 1.8% 
CV for repeated measures of 
FMD% (±SE) 9.77±0.82% 
intraobserver variability CV 1.2% 
to 4.2% 
mean difference 0.88, SD of 
difference 0.82 FMD% 
mean difference 1 FMD%, SD of 
differences 2 FMD%, with a CV 
of 1.4% 
mean difference 1.4 FMD%, 
SE 0.3 FMD% (SD 0.94 FMD%) 
mean difference 3.34 FMD%, SD 
of difference 2.68 FMD% 
repeatability coefficient" 6.93; CV 
10.3% 
reproducibility 5.5% 
variability 1.05±0.35% 
variability 1.9±0.3% 
reference 
11 
2 
12 
13 
14 
15 
16 
14 
17 
18 
19 
20 
' 2xV(IDi2/n) with D=difference between paired scans 
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We recruited 15 healthy volunteers from university students and staff. Health was assessed by 
means of a medical questionnaire; all 15 volunteers were enrolled in the study. Two volunteers 
had to withdraw from the study after the first visit because we could not obtain good quality 
measurements of their brachial artery. The 13 remaining volunteers (3 men, 10 women) aged 18-
43 (mean age 24) years successfully completed the study. 
Design 
Each volunteer was measured on 6 occasions, with a maximum of 16 d (mean 5.4 d) in between. 
They all completed the study within 6 weeks. No food and caloric drinks were allowed after 8pm 
and no water after 10pm the night before the measurements. The measurements were carried 
out between 7.15am and 10.30am and appointment times were kept constant for each subject 
throughout the study. They recorded illness and use of medication in a diary. 
FMD measurement 
We obtained images of the brachial artery with a 7.5 MHz linear-array transducer of an 
Ultramark-5 ultrasound system (ATL Woerden, the Netherlands). All images were recorded on 
super VHS videotape for off-line analysis. One sonographer performed all the measurements 
and one reader analysed all the videotapes. 
The method we used was similar to the one described by Celermajer et al8. The 
measurements were done at the brachial artery of the right arm, at the site of the antecubital 
crease, with an inflatable cuff around the forearm. Arm and ultrasound transducer were held in 
position with a specially designed fixture (TAF® method developed by Meijer et al. Vascular 
Imaging Center, Julius Center for Patient Oriented Research UMC Utrecht Heidelberglaan 100, 
3584 CX Utrecht). We chose a segment of the artery of at least 5 mm in length with clear lumen 
and distinctive vessel walls. We first recorded 3 baseline images of the brachial artery. We then 
inflated the cuff around the lower arm to a pressure of 240 mm Hg. After 4 minutes we deflated 
the cuff and started image recording. In the next 5 minutes, images of the brachial artery were 
frozen every 15 seconds. Others showed that maximal dilation is reached within 5 minutes2-9-10. 
Off-line analysis and quality of ultrasound images 
The reader traced the trailing edge of the adventitia-media interface at the near wall and the 
leading edge of the media-adventitia interface at the far wall of the brachial artery over a length 
of at least 3 mm. The distance between these interfaces reflects the lumen diameter. All 
ultrasound images were given a quality score (l=excellent, 2=moderate, or 3=insufficient) by the 
reader. These quality scores were based on the presence of clear vessel wall boundaries and 
whether the arm and thus the brachial artery was held in the same position. Only quality scores 1 
and 2 were used for data analysis. 
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Statistical analysis 
Baseline and maximum diameters were measured in millimeters. We report means, standard 
deviations (SD), variances (Var=SD2), and coefficients of variation (CV=SD/meanxlOO%). We 
used the SAS (SAS System for Windows Release 6.12, SAS Institute Inc., Cary, North Carolina, 
USA) procedure 'Proc Anova' with 'subject' as main effect to calculate the within-subject 
variance (MSE=Mean Square Error in SAS output). 
FMD is computed as the increase in diameter divided by the baseline diameter: 
FMD= {(maximum-baseline)/baseline} x 100%. 
The formula can also be written as the ratio between maximum and baseline diameter minus 1: 
FMD= {(maximum/baseline)--!} x 100%. 
The latter formula shows that the FMD is a rescaled ratio between the two diameters. Because 
rescaling by subtraction does not change the variance, only the mean, we also calculated the 
coefficient of variance for the ratio between maximum and baseline diameter. We did this 
because this might explain the small coefficients of variation reported by others (Table 2.1). For 
reasons of clarity we use 'FMD%' as a unit of FMD-measurements and '%' for other 
percentages. 
We estimated the number of subjects needed to detect treatment differences in a cross-over 
study and a parallel study, and group means in an observational study {ref Snedecor}. For a 
cross-over study, we used the estimate N»factorxSD2 /D2 with N=total number of subjects, 
SD=standard deviation of the difference, estimated as "v2xwithin-subject SD, and D=treatment 
difference. The factor is derived from (Za+Zp)2 with probability a = 5 % and (1-p) power=80% 
(factor=7.9) or 90% (factor=10.6). For a parallel study that compares treatment responses 
between groups, we used N«2x8x SD 2 /D 2 with N=number of subjects per group, 
SD=standard deviation of the response within a group, estimated as V2xwithin-subject SD, and 
D=differences between responses. 
Results 
The number of measurements of sufficient quality ranged from 2 to 6 per subject (Table 2.2), 
with a total of 62 out of 78 scans. The remaining 16 scans with low quality were excluded from 
the analysis. The coefficient of variation of the baseline diameter was 4.8% and that of the 
maximum diameter 5.2%, in contrast to the much higher coefficients of variation of the absolute 
increase in diameter (CV=51.1%) and the flow-mediated vasodilation (CV=50.3%) (Table 2.3). 
The coefficient of variation of the ratio between maximum and baseline diameter was 2.7% 
(Table 2.3). 
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Table 2.2 Means with standard deviations (SD) of brachial artery measurements of 
13 healthy volunteers, measured 2-6 times each after an overnight fast 
subject 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
N# 
2 
4 
4 
6 
5 
2 
3 
6 
6 
6 
6 
6 
6 
brachial artery diameter (mm) 
at rest (baseline) 
average SD 
3.526 
4.309 
3.761 
4.189 
4.034 
4.851 
4.619 
3.855 
3.704 
4.519 
3.871 
4.293 
3.682 
0.144 
0.362 
0.187 
0.242 
0.186 
0.090 
0.188 
0.182 
0.128 
0.120 
0.118 
0.186 
0.218 
maximum 
average 
3.760 
4.527 
4.108 
4.437 
4.325 
4.908 
4.966 
4.118 
3.810 
4.719 
4.030 
4.490 
3.944 
SD 
0.117 
0.359 
0.285 
0.220 
0.180 
0.105 
0.339 
0.198 
0.141 
0.169 
0.086 
0.242 
0.280 
Flow-me 
vasodil 
(% of ba 
average 
6.67 
5.09 
9.19 
5.98 
7.26 
1.16 
7.46 
6.82 
2.90 
4.43 
4.16 
4.62 
7.07 
diated 
ation 
seline) 
SD 
1.03 
1.53 
3.87 
1.96 
3.15 
0.30 
3.97 
2.53 
2.67 
2.00 
2.52 
4.58 
2.09 
* N = number of used measurements (high and moderate quality) 
Table 2.3 Overview of brachial artery dimensions, within-subject variabilities, and 
coefficients of variation (CV) of 13 healthy volunteers measured on 6 occasions, each 
occasion after an overnight fast 
baseline 
maximum 
absolute change11 
FMD$ 
ratio* 
mean 
4.060 mm 
4.285 mm 
0.225 mm 
5.6 FMD% 
1.056 
SD (root WISE1) 
0.193 mm 
0.222 mm 
0.115 mm 
2.8 FMD% 
0.028 
CV* 
4.8% 
5.2% 
51.1% 
50.3% 
2.7% 
+
 MSE = mean square error 
* CV = root MSE / mean x100% 
11
 maximum - baseline 
$
 {(maximum-baseline)/baseline}x100% or {(maximum / baseline)-1} x100% 
* maximum / baseline 
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For each subject we subtracted his or her average FMD from the corresponding 2-6 individual 
FMD-measurements and we plotted all 62 differences in a histogram (Figure 2.1). The figure 
shows that 87% (54/62) of repeated measurements were within 4 FMD% of a subject's mean 
FMD (range in differences -6.8 to 6.1 FMD%). 
Figure 2.1: 
Deviations of each 
of the 2-6 repeated 
measurements per 
subject from their 
corresponding 
mean 
12.5n 
10.0-
3 
to 
* 7.5H 
0 
.a 
E 
C 
5.0 
2.5-
0.0-
II i i! • I1 ii 
- 7 - 6 - 5 - 4 - 3 - 2 - 1 0 1 2 3 4 5 6 
deviation in FMD% from mean FMD 
Because we had 62 measurements of 13 subjects, the number of degrees of freedom allocated to 
the within-subject variance was {62-l}-{13-l}=49. The corresponding lower limit of the 95% 
CI for the within-subject variance was 0.70a2 and the upper limit 1.55a27. The corresponding 
95% CI for the within-subject SD (square root of variance) was therefore 2.4 to 3.5 FMD%. 
We calculated sample sizes needed to detect differences in cross-over studies and parallel 
studies (Table 2.4). The number of subjects needed to detect a difference of 2 FMD% with a 
probability of 0.05 and a power of 0.90 would be 42 in a cross-over trial and 83 per group when 
group changes (e.g. responses to treatment) are compared. 
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Table 2.4 number of subjects needed in a cross-over study or a parallel study to 
compare treatment effects ranging from 0.5-3.0 FMD% 
minimum 
difference 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
number of pairs in cross-over 
studyt 
power 0.80 power 0.90 
495 
124 
55 
31 
20 
14 
665 
166 
74 
42 
27 
18 
number of subjects per group 
when comparing responses* 
power 0.80 
991 
248 
110 
62 
40 
28 
power 0.90 
1330 
332 
148 
83 
53 
37 
+
 calculated using the SD of differences between pairs, estimated as 
V2xwithin-subject SD = V2x2.8 FMD%=3.96 FMD% 
* calculated using the SD of responses within groups, estimated as 
V2xwithin-subject SD = V2x2.8 FMD%=3.96 FMD% 
Discussion 
Within-subject variability of flow-mediated vasodilation is large: at a mean FMD of 5.60 F M D % 
of the baseline diameter we found a within-subject SD of 2.82 FMD%. The corresponding 
coefficient of variation, the within-subject SD divided by the mean, was 50%, which is larger 
than those described in the literature (Table 2.1). However, the coefficients of variation that we 
found for the baseline and maximum diameter were about 5%, comparable to those found by 
others2'21. Therefore we think that previously reported coefficients of variation of FMD may 
have been calculated differently. A possibility is that the coefficient of variation of the ratio 
between maximum and baseline diameter has been reported. This ratio is in fact a rescaled 
FMD, because the FMD can be calculated as the ratio minus 1. In our dataset, the ratio between 
maximum and baseline diameter was 1.056 with a within-subject SD of 0.028 and a 
corresponding CV of 2.7%, which is close to the reported CVs (Table 2.1). 
The fact that the coefficient of variation of FMD is larger than that of the baseline or 
maximum diameters can be explained mathematically. By definition, the coefficient of variation 
is the standard deviation divided by the mean. The standard deviation of the absolute change in 
diameter is about the same as that of the baseline and maximum diameter (Table 2.3), and will 
therefore not cause the difference in coefficient of variation. However, the mean of the absolute 
change in diameter is about twenty times smaller than the baseline and maximum diameters. A 
smaller mean in the denominator increases the CV, and the CV could even approximate infinity 
if the mean FMD would be close to zero, for example in patients with coronary heart disease. 
Thus, a large coefficient of variation for FMD measurements is not surprising. 
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The mean FMD in our study was small compared to that found in some other studies, and this 
affects the size of the coefficient of variation. Larger values for FMD have been reported by 
investigators that placed the cuff around the upper arm instead of the lower arm, a difference 
that can be as large as 10 FMD%22>23. Thus, differences in methodology may account for some 
of the difference in coefficients of variation. 
Our estimate of within-subject variability includes biological and analytical variation. We 
could not separate the two because all images were made by one sonographer and read by one 
reader. Therefore it is possible that biological within-subject variability, or day-to-day variability, 
is smaller than the 2.8 FMD% we estimated. We therefore estimated the variation in repeated 
readings of flow-mediated vasodilation, using data of 13 subjects of a later study (Chapter 3). 
Each subject's measurement was read twice by one observer; and for each subject the mean and 
SD for these two readings were calculated. The mean ± SD of these 13 averaged readings was 
3.73±1.98 FMD%. The within-subject SD, or between-readings SD, was 1.27 FMD%, which 
corresponded with a CV of 1.27/3.73xl00%=34%. For comparison, the CV of measurements 
performed on different days was 50%, suggesting that reading variation might be more 
important than biological variation. However, this also means that the variation can be reduced 
both by multiple measurements and by multiple readings of the same measurement 
The sample size calculations showed that large numbers of subjects are needed to detect 
small treatment differences, e.g less than 2FMD%. The number of subjects could be reduced if 
the SD that is used in the sample size equation is reduced. This may be accomplished by 
repeated measurements, because the variance of k repeated measures is 1/k times the original 
variance6. Another possibility is pre-study selection of subjects on the basis of image quality, 
because inclusion of images with low quality increases the within-subject variability (data not 
shown). However, this might introduce bias in the outcome of the study, because we do not 
know whether subjects with higher image quality respond differendy to treatment than other 
subjects. 
In conclusion, studies with flow-mediated vasodilation as an outcome variable may give us 
insight on the effects of drugs or diet components on cardiovascular disease risk. The variability 
within-subjects is crucial for the calculation of sample sizes, and is about 50% of the mean 
FMD. Previous reports of coefficients of variation for FMD in the literature are much smaller 
but may have been erroneous. To improve reproducibility of FMD-measurements we 
recommend duplicate measurements and duplicate reading of the tapes. 
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acids by tf/a/is fatty acids lowers serum 
HDL cholesterol and impairs endothelial 
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A B S T R A C T 
Objectives We tested whether trans fatty acids and saturated fatty acids had different effects 
on flow-mediated vasodilation (FMD), a risk marker of coronary heart disease (CHD). 
Background Consumption of trans fatty acids is related to increased risk of CHD, probably 
through effects on lipoproteins. Trans fatty acids differ from most saturated fatty acids 
because they decrease serum high-density lipoprotein (HDL) cholesterol, and this may 
increase risk of CHD. 
Methods We fed 29 volunteers two controlled diets in a 2x4 weeks randomized cross-over 
design. The 'Trans-diet' contained 9.2 energy percent of trans fatty acids; these were replaced 
by saturated fatty acids in the 'Sat-diet'. 
Results Mean serum H D L cholesterol after the Trans-diet was 0.39 mmol /L (14.8 mg/dL) 
or 2 1 % lower than after the Sat-diet (95% CI, 0.28 to 0.50 mmol/L) . Serum LDL and 
triglycerides concentrations were stable. Mean±SD FMD was 4.4±2.3% after the Trans-diet 
and 6.2±3.0% after the Sat-diet (difference -1.8%, 95% CI, -3.2 to -0.4). 
Conclusions Replacement of dietary saturated fatty acids by trans fatty acids impaired FMD 
of the brachial artery, which suggests increased risk of CHD. Further studies are needed to 
test whether the decrease in serum H D L cholesterol caused the impairment of FMD. 
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Introduction 
When liquid oils are partially hydrogenated to form solid margarines and shortenings, trans 
isomers of fatty acids are formed. In countries such as the USA1-2 and the Netherlands3, trans 
fatty acids constitute 4-7% of dietary fat intake. A high intake of trans fatty acids is associated 
with an increased risk of coronary heart disease (CHD)*". One probable cause is the effect of 
trans fatty acids on serum lipoproteins. Like saturated fatty acids, trans fatty acids increase the 
concentration of serum low-density lipoprotein (LDL) cholesterol7-8. Moreover, and unlike 
saturated fatty acids, trans fatty acids decrease serum high-density lipoprotein (HDL) cholesterol7-
". This might be harmful because there is increasing evidence that HDL cholesterol is inversely 
related to CHD12-13. 
We investigated whether the intake of trans fat would indeed increase the risk of CHD more 
than the intake of saturated fat by comparing the effects of these fats on endothelial function, a 
surrogate cardiovascular endpoint14-16. We assessed endothelial function as flow-mediated 
vasodilation (FMD) of the brachial artery, because this is a non-invasive measurement which 
correlates well with known risk factors17-22 and other markers of CHD23-25. Moreover, two 
longitudinal studies show an association between FMD in the past with future CHD events26,27. 
The diets were given for a minimum of 3 weeks; a time period long enough to establish changes 
in serum lipids28 and FMD21. We hypothesized that FMD would be lower after the diet rich in 
trans fat than after the diet rich in saturated fat because of the expected difference in serum HDL 
cholesterol. 
Methods 
Subjects 
The Medical Ethical Committee of Wageningen University approved the study aim and design. 
Each volunteer signed an informed consent form. We recruited 39 non-smoking men and 
women and assessed their health using a questionnaire; we eliminated 1 person because of use of 
medication, 2 because of missing information, and 1 because of poor veins for venipuncture. All 
subjects had normal concentrations of serum cholesterol and triglycerides and normal amounts 
of protein and glucose in their urine. We excluded 2 subjects because we could not obtain a clear 
ultrasound image of their brachial artery. One other subject withdrew before the start of the 
study; in the end, 32 subjects were enrolled. They all completed the study. 
Study design 
We provided 2 controlled diets for 4 weeks each in a randomized cross-over design. The diets 
consisted of conventional food items supplemented with special margarines, and were given in a 
28-day menu cycle. On Mondays through Fridays subjects came to our dining room and ate a 
hot meal under our supervision. All other foods (bread; margarine; meat and/or cheese; honey, 
jam, or sprinkles; fruit; milk and/or yogurt) were packed for consumption at home, as was food 
for the weekends. 
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Habitual energy intake of the subjects was estimated from a food frequency questionnaire. We 
designed menus for 14 levels of energy intake, ranging from 7-20 MJ/d, and allocated the 
subjects to an intake level close to their habitual energy intake. We provided 90 percent of 
energy (en%); all this food was weighed out for each subject We measured body weight twice a 
week; if body weight changed >1 kg subjects were switched to a different energy intake level. 
The remaining 10 en% had to be chosen from a list of low-fat food items and recorded in a 
diary. Subjects received the diets for 21-32 days (mean 27.5 days). 
Diets 
The experimental diets differed in margarine only (Table 3.1). The margarine in the diet rich in 
trans fatty acids was a blend of 70 parts partially hydrogenated soy oil, containing 44% trans-
C18:l (Gouda's Glorie, Van Dijk Foods, Lopik, the Netherlands); 14 parts vegetable oil 
containing 63% linoleic acid and 23% oleic acid (Becel, Unilever, Vlaardingen, the Netherlands) 
and 16 parts water. The margarine in the diet rich in saturated fat was a blend of 60 parts palm 
kernel fat (Loders Croklaan, Wormerveer, the Netherlands) and 40 parts commercially available 
margarine made from a blend of vegetable oils and solid vegetable fats (Blue Band, Van den 
Bergh BV, Rotterdam, the Netherlands). Both margarines were produced at NIZO Food 
Research (Ede, the Netherlands). The margarines were used as shortenings in bread and cookies, 
in sauce and gravy, and as a spread. They supplied 62% of fat in the diets, the remaining 38% 
was mainly derived from meat, cheese and other dairy products, eggs, and salad dressings. 
Table 3.1 Fatty acid composition of the margarines used in 
fatty acids and the diet rich in saturated fatty acids 
Fatty Acid 
Saturated 
Laurie acid (C12:0) 
Myristicacid (C14:0) 
Palmitic acid (C16:0) 
Stearic acid (C18:0) 
c/s-Monounsaturated 
Oleic acid (c/s-C18:1n-9) 
frans-Monounsaturated 
frans-C18:1 
Polyunsaturated 
Linoleic acid (c/s,c/s-C18:2) 
Others 
g/100g Fatty Acid 
Trans margarine 
30.5 
not detected 
0.1 
10.5 
18.5 
18.6 
8.0 
41.4 
40.91 
8.7 
8.2 
1.3 
the diet rich in trans 
Sat margarine 
63.1 
24.5 
10.2 
17.0 
7.4 
20.9 
19.9 
0.6 
0.3 
15.0 
14.6 
0.6 
1
 mainly n-10 (22%), n-9 (20%), and n-11(17%) isomers 
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The composition of the diets was calculated using food composition tables3-29'30 and checked by 
collecting duplicates of all meals (Table 3.2). The analyzed values were similar to the calculated 
composition. 
Table 3.2 Analyzed composition of the two experimental diets 
Fatty Acid 
Carbohydrate (energy%) 
Protein (energy%) 
Total fat (energy%) 
Saturated 
Laurie acid (C12:0) 
Myristic acid (C14:0) 
Palmitic acid (C16:0) 
Stearic acid (C 18:0) 
Monounsaturated, total 
c;s-C18:1 
frans-C18:1 
total trans 
Polyunsaturated 
Linoleic acid (c;s,c/s-C18:2) 
Linolenic acid (c/s,c/s,c/s-C18:3) 
Cholesterol (mg/MJ) 
Cholesterol (mg/day) 
Fibre (g/MJ) 
Fibre (g/day) 
Energy (MJ/day) 
Energy (kcal/day) 
Trans-diet 
48.6 
14.0 
37.4 
12.9 
0.3 
0.8 
5.7 
5.3 
18.2 
8.4 
9.2 
9.4 
4.7 
4.1 
0.3 
27.0 
248.4 
3.2 
29.4 
9.20 
2199 
Sat-diet 
45.6 
13.5 
41.0 
22.9 
6.8 
3.8 
7.8 
3.1 
8.8 
7.9 
0.3 
0.4 
6.9 
5.9 
0.7 
26.8 
253.5 
3.1 
29.3 
9.46 
2261 
Blood lipids 
We took blood samples after an overnight fast on two separate days after day 19 of each diet. All 
4 blood samples of each subject were analyzed in duplicate within 1 run. Total cholesterol and 
triglycerides (Cholesterol Flex™ and Triglycerides Flex™ reagent cartridge, Dade Behring, 
Newark USA) and HDL cholesterol {liquid N-geneous™ HDL-C assay, Instruchemie BV, 
Hilversum, the Netherlands) were measured, and LDL cholesterol was calculated with the 
Friedewald formula. The coefficient of variation of 64 duplicate measurements was 0.4% for 
total cholesterol, 1.5% for triglycerides, and 1.1% for HDL cholesterol. 
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Brachial artery measurements 
All subjects had an overnight fast of at least 12 h before the measurements. We measured FMD 
of the brachial artery as described by Celermajer et a/.22-31. We used the diameter of the artery at 
rest and at maximum vasodilation to calculate the percentage increase or FMD. All 
measurements were done at end diastole by the use of the R-wave of the electrocardiogram. The 
ultrasound images were made by one technician with a 7.5 MHz linear array transducer of an 
Ultramark™ 9 HDI duplex scanner. All images were stored on super-VHS videotapes for off-
line analysis. 
Subjects were made to lie down in a temperature-controlled room (range 20-23°Q with the 
right arm in two arm support cushions. An inflatable cuff was placed around the lower arm. The 
transducer was held in position at the site of the antecubital crease with a specially developed 
transducer arm fixature (TAF® method developed by Meijer et al. Vascular Imaging Center, The 
Julius Center for Patient Oriented Research UMC Utrecht Heidelberglaan 100, 3584 CX 
Utrecht). 
We first obtained an optimal two-dimensional B-mode ultrasound image of the brachial 
artery at rest and recorded three images to measure the diameter. We then inflated the cuff to 
250 mm Hg and kept this pressure constant for 5 minutes to induce ischemia in the forearm and 
hand. After 5 minutes the cuff was deflated. The image of the brachial artery was optimized and 
changes in the diameter of the artery were recorded during the next 5 minutes. Every 15 seconds 
a frozen image was stored on videotape. At the end of the second feeding period we also 
measured endothelium-independent vasodilation after a sublingual dose of 400 ug of 
nitroglycerin. 
One reader who was blinded to the treatment read all images at the Vascular Imaging Center 
of the University Medical Center in Utrecht The reader rated the quality of the images from 
class 1 (perfect) to class 4 (unfit for use). All 32 subjects were measured twice on both diets, so 
we had 4 measurements per subject Of these 128 measurements, 24 were rated as perfect, 71 as 
fair, 26 as marginal, and 2 as unfit Five measurements were missing. We only used 
measurements rated perfect or fair, which left us with 29 subjects for whom we had 
observations on both diets. At a mean FMD of 5.3% of the resting diameter, the SD within-
subjects was 2.6%-points so the corresponding CV was 49%. The largest difference in a 
duplicate FMD-measurement was 18.2%-points (FMD 2.6 and 20.8% of the resting diameter); 
the smallest difference 0.16%-points (measurements: 7.2 and 7.4% of the resting diameter). The 
CV of the resting and maximum diameter was 8%. 
Statistics 
We averaged the duplicate measurements in each dietary period and tested for order effects by 
ANOVA, with diet and order as main effects in the model32. Because the order of the two diets 
did not significandy contribute to the model, we then calculated for each subject the difference 
between treatments. We tested whether these differences were significandy different from zero 
by the Student t test for paired samples. We give two-sided 95% confidence intervals for the 
differences. 
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Results 
We analyzed data of 29 subjects, 10 men and 19 women. Their mean (±SD) age was 30±16 
years, their mean weight 69±9 kg, and their mean body mass index 22.5±2.4 kg/m2. Pre-study 
serum cholesterol concentrations were 5.1+1.1 mmol/L and serum triglycerides 1.2±0.7 
mmol/L. 
Body weight 
During the 4-week feeding periods, body weight remained basically stable, with mean decreases 
of 0.4 kg during the Trans-diet and 0.6 kg during the Sat-diet (P=0.43 for difference in change 
between diets). 
Blood lipids 
Serum HDL cholesterol decreased from 1.87±0.46 mmol/L (73.1 ±17.8 mg/dL) on the diet rich 
in saturated fats to 1.49±0.33 mmol/L (56.5±12.8 mg/dL) on the diet rich in trans fats (Table 
3.3). The decrease was 0.39 mmol/L (95% CI, -0.50 to -0.28) or 21%. Serum LDL cholesterol 
and triglycerides remained stable. The order of the two diets hardly affected the change in HDL 
cholesterol: the mean change was 0.35±0.25 mmol/L in subjects who went from the Trans-diet 
to the Sat-diet and 0.43±0.32 mmol/L in the subjects who received the diets in the reverse 
order. 
Brachial artery measurements 
The diameter of the brachial artery at rest was 4.02±0.70 mm on the Sat-diet and 4.08±0.73 mm 
on the Trans-diet. The maximum diameter was 4.33+0.80 mm on the Sat-diet and 4.19±0.73 
mm on the Trans-diet FMD was 6.2±3.0% on the Sat-diet and 4.4±2.3% on the Trans-diet 
(P=0.015). Thus, FMD was 1.8 percent (95% CI -3.2 to -0.4) or 29% lower on the Trans-diet 
than on the Sat-diet (Figure 3.1). The order of the two diets hardly affected the results: 15 
subjects went from an FMD of 4.8% after the Trans-diet to 6.4% after the Sat-diet whereas 14 
other subjects went from 5.9% after the Sat-diet to 4.2% after the Trans-diet. 
All subjects showed vasodilation after nitroglycerin (range 4.4 to 20.8%). Diet had no effect 
on nitroglycerin-rnediated vasodilation, which was 14.3±3.4% on the Trans-diet and 13.4±5.3% 
on the Sat-diet (unpaired /"test, P=0.64). 
A decrease in HDL cholesterol went together with a decrease in FMD in 18 of 29 subjects. 
The correlation between changes in HDL cholesterol and FMD was positive but not significant 
(r=0.12,95% CI -0.26 to 0.46, P=0.55). 
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Table 3.3 Concentration of serum lipids after 4 weeks consumption of the two diets 
Trans-diet Sat-diet Difference (95% CI) 
total cholesterol 4.97 ± 0.94 
high-density lipoproteins 1.48 ± 0.33 
low-density lipoproteins 3.04 ± 0.80 
triglycerides 0.98 ± 0.41 
concentrations in mmol/L 
5.34 ± 0.95 -0.37 (-0.24 to -0.50) 
1.87 ± 0.45 -0.39 (-0.28 to -0.50) 
3.05 ±0.81 -0.01 (-0.14 to 0.11) 
0.90 ± 0.36 0.08 (-0.04 to 0.20) 
Values are means ± SD. The 29 subjects consumed both diets for 4 weeks in random order. To convert 
values for total, HDL, and LDL cholesterol to milligrams per deciliter, multiply by 38.67. To convert 
triglycerides to milligrams per deciliter, multiply by 88.54 
Figure 3.1: 
Flow-mediated vasodilation 
of the 29 subjects after the 
diet rich in trans fatty acids 
(•) and after the diet rich in 
saturated fatty acids (D). 
The subjects consumed both 
diets for 21-32 days in 
randomized order. 
P=0.015 
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Discussion 
Consumption of trans fatty acids resulted in lower H D L cholesterol and a smaller flow-mediated 
vasodilation than consumption of saturated fatty acids. This might explain the increased risk of 
cardiovascular disease at high intakes of trans fatty acids. However, the question remains whether 
the impaired vasodilation was attributable to the decrease in H D L cholesterol. 
HDL cholesterol, other dietary factors, and endothelial function 
There is some evidence that changes in HDL cholesterol concentration could change endothelial 
function. First, higher serum HDL cholesterol is associated with better endothelial 
function24-33.34. This might be due to the proposed antioxidant capacity of HDL3 5 which might 
prevent oxidation of LDL and therefore prevent adverse effects of oxidatively modified LDL on 
endothelial function. We know of no other interventions aimed at HDL, but other antioxidants, 
such as vitamin C36-37 were shown to improve FMD. Second, there is ample evidence that 
reductions in other known risk factors, such as LDL cholesterol21-25-38 or homocysteine39, 
improve FMD, suggesting that changes in HDL cholesterol could have similar effects. The fact 
that we did not find a significant correlation between changes in HDL cholesterol and FMD 
does not rule out a causal relation, because the data were too scarce to correct for possible 
confounding variables such as gender and age. On the other hand, a significant correlation 
would be no proof of a causal relation. 
Other factors in the diets might account for the effect on FMD. As shown in Table 3.2 there 
was a small difference in linoleic acid between the two diets, and studies with rats show that trans 
fatty acids have stronger effects at low intakes of linoleic acid40. Although this might apply to 
man, those rat studies were done at very high intakes of trans fatty acids (20en%), and the 
adverse effects could be counteracted with a linoleic acid intake as low as 2en%. Thus, the 
4.1en% provided by linoleic acid in our 9.2en% Trans-diet was not low as compared to the rat 
studies. Also, we think that the difference in linoleic acid between the Sat en Trans-diet was too 
small to fully explain the effects seen on FMD. Another factor is vitamin E; the different fat 
mixtures likely differed by 10-20 mg/lOOg. However, studies that showed an effect of vitamin E 
on FMD41 used much higher doses, and even at these high doses most studies did not show an 
effect42-44. Lastly, FMD is impaired in diabetes45 and if trans fatty acids and saturated fatty acids 
have different effects on insulin metabolism this could have biased the results. However, it is 
unlikely that fasting serum insulin was different between the two diets46. 
We do not know of studies that compared long-term effects of different fats on FMD. 
Postprandial effects of saturated and #J"-monounsaturated fats seem to be similar; they all appear 
to impair FMD compared to pre-prandial values or compared to low-fat control meals36-47-48. 
However, some of these studies36-47 are flawed because the low-fat meals had a higher vitamin C 
content than the fat-enriched meals which might have improved FMD49. We know of no short-
term effects of trans fatty acids on FMD. 
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Study limitations 
We used a cross-over design to eliminate variation due to differences between subjects. The 
order of the two diets was balanced and randomized per subject to eliminate bias due to a 
systematic drift of the outcome variables over time32. Although we did not include a wash-out 
period, we did not find a significant order effect on any of the blood lipoproteins or for FMD. 
We were only interested in differences between the two test diets; not in changes from the 
habitual diet, and therefore no baseline data were collected. We can only speculate on changes in 
blood lipoproteins and FMD from baseline. Both experimental diets differed in fat content from 
habitual diets: The amount of trans fatty acids in the Trans-diet was about 23 g/d, which is 5-fold 
higher than the estimated 4.8 g/d for men and 3.8 g/d for women in the Netherlands3. The 
amount of saturated fat in the Sat-diet was 58 g/d which is also higher than the habitual intake 
of 42 g/d for men and 32 g/d for women in the Netherlands. Because of the low habitual intake 
of trans fatty acids, replacing them all by saturated fatty acids would probably hardly improve 
endothelial function. Conversely, our findings imply that replacing all saturated by trans fatty 
acids could impair FMD and should therefore be discouraged. 
The inclusion of women in the study may have increased the variation in FMD response, 
because changes in serum oestradiol concentrations affect FMD50. However, we minimized this 
variation with 4-week study periods, the length of a menstrual cycle. The women appeared to 
respond stronger to the diets, with a 2.3%-units (95% CI, 0.4 to 4.2) smaller FMD on the Trans-
diet than on the Sat-diet, than the men in who the difference was 0.8%-units (95% CI, —1.3 to 
3.0). However, the number of men was small (n=10) and therefore our study was not powered 
to test for gender differences. Further studies with larger numbers of men and women are 
needed to test for differences in response. 
Repeatability of the FMD-measurement 
We found a mean FMD of 5.3%. This is somewhat lower than values for healthy volunteers 
reported by others16"36'50, but differences in methodology, for example the position of the 
inflatable cuff51, could account for this. The variability in FMD was high, we found a coefficient 
of variation of 49%. This is comparable with the variability found in some studies52-53, but higher 
than values reported by others23'31'50-54-55. However, in most papers it is unclear how the values 
for variability have been calculated. 
In conclusion, we showed that replacement of saturated fatty acids by trans fatty acids in the 
diet lowered serum HDL cholesterol and impaired FMD. This suggests that trans fatty acids 
increase risk of CHD more than intake of saturated fats with similar effects on LDL cholesterol. 
Further studies are needed to verify whether decreases in HDL cholesterol indeed impair 
endothelial function and thereby explain the increased risk of CHD at high intakes of trans fats. 
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A B S T R A C T 
Background Low-fat diets, in which carbohydrates replace some of the fat, decrease serum 
cholesterol. This decrease is due to decreases in LDL cholesterol but in part to possibly 
harmful decreases in H D L cholesterol. High-oil diets, in which oils rich in monounsaturated 
fat replace some of the saturated fat, decrease serum cholesterol mainly through LDL 
cholesterol. 
Methods We used these two diets to investigate whether a change in H D L cholesterol would 
change flow-mediated vasodilation, a marker of endothelial function. We fed 32 healthy 
volunteers two controlled diets in a 2x3V2 weeks randomised cross-over design to eliminate 
variation in changes due to differences between subjects. The low-fat diet contained 58.2 
percent of energy (en%) as carbohydrates and 25.0 en% as fat (7.5 en% as oil); the oil-rich 
diet contained 36.5 en% as carbohydrates and 42.4 en% as fat (18.4 en% as oil). 
Results Average (±SD) serum H D L cholesterol after the low-fat diet was 0.21 ±0.12 
mmol /L (8.1 mg/dL) lower than after the oil-rich diet. Serum triacylglycerols were 
0.22±0.28 mmol /L (19.5 mg/dL) higher after the low-fat diet than after the oil-rich diet. 
Serum LDL and homocysteine concentrations remained stable. Flow-mediated vasodilation 
was 4.8±2.9% after the low-fat diet and 4.1 ±2.7% after the oil-rich diet (difference 0.7%; 
95% CI, -0.6 to 1.9%). 
Conclusion Although the low-fat diet produced a lower H D L cholesterol than the high-oil 
diet, flow-mediated vasodilation, an early marker of cardiovascular disease, was not impaired. 
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Introduction 
Diets low in saturated fats and high in carbohydrates are often advocated to reduce the risk of 
cardiovascular disease (CVD) because they lower serum total and LDL cholesterol13. However, 
there has been a debate about whether to lower the intake of saturated fats by decreasing total 
fat intake or by replacing them with alr-unsaturated fats. Supporters of low-fat diets argue that 
replacement of fat by carbohydrates will not only decrease risk of CVD through lowering of 
serum cholesterol but will also help people lose weight4 and thus prevent obesity5'6. However, 
others argue that low-fat diets might not be the wisest recommendation because these diets 
lower HDL cholesterol7, which may increase the risk of coronary heart disease8-17. HDL 
cholesterol is not lowered when saturated and trans fatty acids are replaced by unsaturated 
vegetable oils, and therefore diets rich in vegetable oils might be a good alternative to low-fat 
diets7. 
To investigate whether the difference in HDL cholesterol after a low-fat diet and a high-oil 
diet would affect risk of cardiovascular disease, we used flow-mediated vasodilation of the 
brachial artery as an outcome variable. Flow-mediated vasodilation is a measure of endothelial 
function, which is believed to be an early stage of cardiovascular disease18,19. Flow-mediated 
vasodilation of the brachial artery is mediated by nitric oxide released by the endothelial cells20 
and can be measured non-invasively. We chose flow-mediated vasodilation (FMD) because it 
appears to be predictive of cardiovascular events21. 
In a previous study (Chapter 3) we showed that intake of trans fatty acids reduced serum 
HDL cholesterol and impaired flow-mediated vasodilation in healthy men and women. 
Although the results of that study seemed to be compatible with a causal relationship between 
HDL cholesterol and FMD, a verification of the results was needed. Thus, we investigated 
whether the difference in HDL cholesterol after a low-fat diet and a oil-rich diet affected flow-
mediated vasodilation. We applied Bayesian methods to integrate the existing evidence for a 
protective effect of HDL cholesterol with the present data. 
Methods 
The study was approved by the Medical Ethics Committee of Wageningen University. Each 
volunteer signed an informed consent form. 
Subjects 
We recruited 39 non-smoking men and women by advertising in the university paper and by 
personally inviting subjects who had taken part in previous studies. We selected subjects on the 
basis of a medical questionnaire, serum cholesterol (<8mmol/L) and triacylglycerol 
(<2mmol/L) , urinary protein (<0.3g/L) and glucose (<5.5 mmol/L), and a good quality 
ultrasound image of the brachial artery. We enrolled 35 subjects. One subject withdrew from the 
study after 1 week because he was unable to comply with the study protocol. The study was 
completed by 34 subjects; 13 men and 21 women with mean age 27 (range 19-59) years. Their 
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mean (+SD) baseline body weight was 68±9 kg, body mass index 22+23 kg/m2, fasting total 
cholesterol 4.6±0.8 mmol/L and triacylglycerols 1.2±0.5 mmol/L. 
Study design 
Our aim was to test whether a difference in HDL cholesterol induced by two different diets 
would result in a difference in FMD. To minimize the variation in the differences we chose a 
cross-over design. The order in which the two diets were given was randomly allocated. 
We provided 2 controlled diets for 3V2 weeks each without a wash-out period. The diets were 
given in a 28-day menu cycle. On Mondays to Fridays subjects came to our dining room and ate 
a hot meal under our supervision. All other foods (bread; margarine; meat and/or cheese; honey, 
jam, or sprinkles; fruit; milk and/or yogurt) were provided in a package for consumption at 
home, as was food for the weekends. 
On 2 days during the last week of each diet period, after subjects had consumed the diets for 
at least 22 days, we measured flow-mediated vasodilation and serum lipids of the subjects. The 
measurements were performed 1-2 days apart Because not all subjects could be measured on 
the same day, they received the diets for 24-27 days (mean 25 days). 
Diets 
The two diets consisted of conventional food items. The composition of the two diets was 
calculated to change the concentration of HDL cholesterol without changing LDL cholesterol. 
Therefore, it was impossible to match the two diets for saturated and poly-unsaturated fatty acid 
intake. We used a low-fat margarine, low-fat dairy products, and extra carbohydrate in the low-
fat diet, and olive oil, margarine, and full-fat dairy products in the oil-rich diet (Table 4.1). The 
composition of the experimental diets was calculated using food composition tables22-23. We 
checked the composition of the diets by collecting duplicates of all meals. The analyzed values 
were similar to the calculated composition (Table 4.2). 
Habitual energy intake of the subjects was estimated from a food frequency questionnaire. 
We designed menus for 14 levels of energy intake, ranging from 7 to 20 MJ per day. The 
subjects were allocated to an energy intake level close to their habitual energy intake. We 
provided 90 percent of energy and all food was weighed out for each subject. The remaining 10 
percent of energy had to be chosen from a list of low-fat food items. Subjects recorded their 
choice from this low-fat food list in a diary. We measured body weight twice a week; if body 
weight changed more than 1 kg subjects were switched to a different energy intake level. 
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Table 4.1 Food items (g/day) provided in a 11-MJ menu of the low-fat- and oil-rich diet 
food items that differed in 
amount and composition 
foods that differed in 
amount only 
food item 
bread' 
cookies" 
sauce and gravy" 
salad dressing1 
dessert* 
table spread 
starch (potatoes, rice 
bulgur) 
vegetables 
fruit 
salad 
meat 
milk, 1.5% fat 
eggs 
cheese, 31% fat 
meat (filling) 
pasta, 
sweet fillings (honey, jam, 
sprinkles, etc) 
crisps 
low-fat diet 
233.0 
30.0 
70.0 
15.0 
250.0 
26.0 
270.0 
230.0 
248.0 
38.0 
82.0 
250.0 
17.5 
16.0 
36.0 
39.0 
9.0 
oil-rich diet 
200.0 
45.0 
70.0 
15.0 
125.0 
35.0 
180.0 
180.0 
124.0 
38.0 
68.0 
200.0 
28.0 
32.0 
36.0 
26.0 
9.0 
Made with margarine (Blueband, Unilever, Vlaardingen, the Netherlands) in the low-fat diet 
and with olive oil (Carbonell, Cordoba, Spain) in the oil-rich diet. 
f
 Made with low-fat salad dressing (5 g fat/100 g) in the low-fat diet and with olive oil in the oil-
rich diet. 
t Low-fat desserts in the low-fat diet and full-fat desserts in the oil-rich diet. 
5
 Low-fat margarine (35 g fat/100 g) in the low-fat diet and full-fat margarine (80 g fat/100 g) in 
the oil-rich diet. 
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Table 4.2 Diet composition in the low-fat and in the unsaturated oil-rich 
period. In both periods 90% of energy was provided and duplicate meals 
were analyzed. The remaining 10% of energy was chosen from a list of low-
fat food items and the composition of these was calculated 
Component 
Energy (MJ/day) 
Energy (kcal/day) 
Carbohydrate (energy%) 
Protein (energy%) 
Total fat (energy%) 
Saturated 
Laurie acid (C12:0) 
Myristicacid(C14:0) 
Palmitic acid (C16:0) 
Stearic acid (C18:0) 
Monounsaturated, total 
Polyunsaturated 
Cholesterol (mg/MJ) 
Cholesterol (mg/day) 
Fibre (g/MJ) 
Fibre (g/day) 
Alcohol (en%) 
low-fat diet 
11.4 
2702 
59.7 
13.4 
25.7 
10.3 
0.8 
0.9 
5.7 
2.2 
7.8 
6.9 
25.9 
294 
2.6 
29.5 
1.3 
oil-rich diet 
11.3 
2693 
37.8 
16.4 
44.4 
15.5 
1.3 
1.5 
7.9 
3.7 
19.3 
8.8 
34.1 
386 
2.4 
27.1 
1.2 
Blood lipids 
We took fasting blood samples on two separate days after day 22 of each diet. All 4 blood 
samples of each subject were analyzed in duplicate within 1 run. Total cholesterol and 
triacylglycerols (Cholesterol Flex™ and Triglycerides Flex™ reagent cartridge, Dade Behring, 
Newark USA) and HDL cholesterol {liquid N-geneous™ HDL-C assay, Instruchemie BV, 
Hilversum, the Netherlands) were measured, and LDL-cholesterol was calculated with the 
Friedewald-formula. The coefficient of variation of 64 duplicate measurements was 0.4% for 
total cholesterol, 1.5% for triacylglycerols, and 1.1% for HDL cholesterol. 
Brachial artery measurements 
All brachial artery measurements were done in subjects after an overnight fast. We assessed 
endothelial function as flow-mediated vasodilation (FMD) of the brachial artery as described 
elsewhere 24?s. We measured the diameter of the artery at rest and at maximum vasodilation, and 
calculated the FMD as the percentage increase. All measurements were done at end-diastole by 
the use of the R-wave of the ECG. 
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The ultrasound images were made with a 7.5 MHz linear array transducer of an Ultramark™ 9 
HDI duplex scanner. All images were stored on super-VHS videotapes for off-line analysis. All 
measurements were done by one technician in a temperature-controlled room (range 20°C to 
24°C). Subjects were lying down with the right arm in two arm support cushions. An inflatable 
cuff was placed around the forearm. The measurements were done at the site of the antecubital 
crease. The position of the transducer was held constant during the measurements with a 
specially developed transducer arm fixature (TAF method developed by Meijer et al, Vascular 
Imaging Center, The Julius Center for Patient Oriented Research, UMC Utrecht, the 
Netherlands). 
We first obtained an optimal two-dimensional B-mode ultrasound image of the brachial 
artery at rest The search was for a good trailing edge of the adventitia interface of the near wall 
and a leading edge of the media-adventitia interface of the far wall of the artery. Three optimal 
images were frozen at the R-wave of the ECG, at end-diastole, and stored on videotape. These 
images were used to calculate the resting diameter of the artery. We then inflated the cuff to 
250 mmHg and kept this pressure constant for 5 minutes to induce ischemia in the forearm and 
hand. After 5 minutes the cuff was deflated. The image of the brachial artery was again 
optimised and changes in the diameter of the artery were recorded during the next 5 minutes. 
Every 15 seconds a frozen image was stored on videotape. At the end of the second feeding 
period we also measured endothelium-independent vasodilatation after a sublingual dose of 400 
ug of nitroglycerin. 
All images were read at the Vascular Imaging Center of the University Medical Center in 
Utrecht by one reader who was blinded to the treatment. The reader rated the quality of the 
images as class 1 (perfect), class 2 (fair), class 3 (marginal) to class 4 (unfit for use). All 34 
subjects were measured twice on both diets, so we had 4 measurements per subject Of these 
136 measurements, 16 were rated as marginal and 3 as unfit We only used measurements rated 
perfect or fair, which left us with 32 subjects for whom we had observations on both diets. At a 
mean FMD of 4.5%-units, the within-subjects SD was 2.9%-units so the corresponding 
coefficient of variation was 65%. The biggest difference between duplicate FMD-measurements 
was 9%-units (measurements: -8.05 and 0.95%-units); the smallest difference 0.01%-units 
(measurements: 2.83 and 2.82 %-units). The coefficient of variation of the diameter of the 
brachial artery at rest was 6.9%. 
Serum homocysteine 
Total homocysteine concentrations in serum were measured with high-performance liquid 
chromatography and fluorimetric detection26-27. The coefficient of variation was 3.2% within and 
8% between runs. 
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Statistics 
We averaged the duplicate measurements in each dietary period and then calculated for each 
subject the difference between treatments. We tested whether these differences were 
significantly different from zero by the Student ^test for paired samples. We give two-sided 95% 
confidence intervals for the differences. All statistical analyses were performed with the SAS 
System for Windows (SAS Institute Inc., Cary, NC, USA), release 6.12. 
We used Bayesian statistics to combine existing evidence for a protective effect of HDL 
cholesterol with the present data. The existing evidence was used to postulate a prior probability 
(i.e. before the present study) for a direct effect of HDL cholesterol on flow-mediated 
vasodilation. We postulated a prior probability of 75%. The effect-size was estimated from data 
of our previous study (Chapter 3): we hypothesised that flow-mediated vasodilation would be 1 
%-unit lower on the low-fat diet than on the high-oil diet The rationale behind this hypothesis 
was that in the previous study a decrease in HDL cholesterol of 0.36 mmol/L went together 
with a decrease in FMD of 1.8 %-units. In the present study we expected to see a decrease in 
HDL cholesterol of 0.20 mmol/L on the low-fat diet and therefore a decrease in FMD of 1 %-
unit (1/0.2=1.8/0.36). We used the Bayes factor, which was derived from the p-value of the 
Student t test, to evaluate whether the data from the present study changed the prior probability 
28 
Results 
All results refer to 11 men and 21 women for whom data were complete (data for 2 men were 
incomplete). They had a mean age of 26.8+12.8 (SD) years, a mean pre-study weight of 
68.5±8.6 kg, and a mean body mass index of 22.1 ±2.2 kg/m2. 
Body weight and food intake 
Body weight was fairly constant during the study and hardly differed between the two diet 
periods: the average body weight was 68.7±8.7 kg after the oil-rich diet and 68.6±8.7 kg after the 
low-fat diet. On average subjects consumed 10.2 MJ/d of the experimental diets that were 
provided by us. They consumed an additional 1.1 MJ/d of free choice low-fat food items. 
Blood lipids 
Serum HDL cholesterol was 0.21 mmol/L (8.1 mg/dL) lower after the low-fat diet than after 
the oil-rich diet (95% CI, -0.26 to -0.17 mmol/L). Serum total cholesterol was 0.14 mmol/L 
lower after the low-fat diet than after the oil-rich diet (95% CI, -0.27 to -0.01 mmol/L). In 
contrast, serum triacylglycerols were 0.22 mmol/L higher after the low-fat diet than after the oil-
rich diet (95% CI, 0.12 to 0.32 mmol/L). Serum LDL-cholesterol remained stable (Table 4.3). 
The order of the two diets hardly affected the change in HDL cholesterol: the mean change 
was -0.23±0.14 mmol/L in subjects who changed from the low-fat to the oil-rich diet and 
0.20±0.13 mmol/L in subjects who received the diets in the reverse order. 
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Table 4.3 Concentration of serum lipids (mmol/L) after consumption of the two diets 
oil-rich diet 
mean SD 
low-fat diet 
mean SD 
Difference (95% CI) 
total cholesterol 
HDL cholesterol 
LDL cholesterol 
triacylglycerols 
4.48 
1.66 
2.45 
0.81 
0.87 
0.39 
0.65 
0.41 
4.34 
1.44 
2.42 
1.03 
0.84 
0.35 
0.67 
0.52 
-0.14 (-0.27 to-0.01) 
-0.21 (-0.26 to-0.17) 
-0.03 (-0.12 to 0.07) 
0.22 (0.12 to 0.32) 
Values are means±SD. The 32 subjects consumed both diets for ZVz weeks in random order. To convert values 
for total, HDL, and LDL cholesterol to milligrams per deciliter, multiply by 38.67. To convert triacylglycerols to 
milligrams per deciliter, multiply by 88.54 
Table 4.4 Brachial artery measurements after both diets. None of the differences 
between the diets was statistically significant (P<0.05) 
oil-rich diet 
mean SD 
low-fat diet 
mean SD 
resting diameter (mm) 
maximum diameter (mm) 
absolute vasodilation (mm) 
flow-mediated vasodilation (%)" 
endothelium-independent dilation (%) 
systolic blood pressure (mm Hg) 
diastolic blood pressure (mm Hg) 
3.91 
4.07 
0.16 
4.13 
11.9 
121.9 
72.2 
0.68 
0.69 
0.10 
2.72 
7.3 
11.2 
9.1 
3.95 
4.13 
0.18 
4.80 
10.0 
120.4 
71.0 
0.55 
0.55 
0.10 
2.94 
5.1 
11.5 
7.4 
calculated for each subject as absolute vasodilation divided by resting diameter x100%. 
Table 4.5 Change in prior probabilities, ranging from weak to strong, to posterior probabilities 
using data of the present study. Prior probabilities were first converted to prior odds. The prior 
odds were then multiplied by the Bayes factor to obtain a posterior odds. Finally, the posterior 
odds were converted to posterior probabilities 
prior probability prior odds posterior odds posterior probability 
0.75 (strong) 0.75/(1-0.75) = 3 3x Bayes factor = 0.12 0.12/(1+0.12) = 0.11 
0.50 (equivocal) 0.50/(1-0.50) = 1 1x Bayes factor = 0.042 0.042/(1+0.042) = 0.04 
0.25 (weak) 0.25/(1-0.25) = 0.33 0.33x Bayes factor = 0.014 0.014/(1+0.014) = 0.014 
Bayes factor = e to the power z2/2, where z is the z-score of the p-value for obtaining a result as large as 
+0.67 %-units under the hypothesis that the result would be -1.0 %-units. P-value = 0.0119, z-score = 2.52 
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Brachial artery measurements 
The resting and maximum diameter of the brachial artery were hardly affected by the type of 
diet (Table 4.4). Flow-mediated vasodilatation was slighdy better after the low-fat diet than after 
the oil-rich diet: 4.8±2.9% versus 4.13±2.7% (P=0.29), which was a difference of-0.67 %-units 
(95% CI, —1.94 to 0.61). Subjects who changed from the oil-rich diet to the low-fat diet showed 
a bigger change in FMD (1.26 %-units) than subjects who received the diets in reversed order 
(0.08 %-units). 
All subjects showed vasodilation after nitroglycerin (range 1.1 to 26.4%), indicating that their 
smooth muscle cells were able to respond to nitric oxide. The type of diet had hardly any effect 
on nitroglycerin-mediated vasodilation, which was 10.0±5.1% after the low-fat diet and 
11.917.3% after the oil-rich diet 
Serum homocysteine measurements 
Serum homocysteine concentrations were not affected by the difference in the two diets: 
concentrations after the low-fat diet were 10.0±2.5 umol/L and after the oil-rich diet 10.1 ±2.7 
umol/L (difference 0.2 umol/L, 95% CI, -0.3 to 0.6 umol/L). 
Bayesian interpretation 
Before the study we postulated that flow-mediated vasodilation would be 1 %-unit lower after 
the low-fat diet than after the oil-rich diet We gave this hypothesis a prior probability of 75%, 
which corresponds with a prior odds of 0.75/(1 -0.75)=3. From our data we calculated that the 
probability P of finding an effect of -0.67 %-units under this hypothesis was 0.29. A P-value of 
0.29 corresponds with a ^-score of 2.52 and a minimum Bayes-factor of 0.04. This Bayes-factor 
was used to correct the prior odds into a posterior odds by multiplication. Thus, the posterior 
odds for the hypothesis was 0.04x3=0.12, which corresponded with a posterior probability of 
the hypothesis of 0.12/(1+0.12)=0.11 or 11% (Table 4.5). Consequendy, smaller prior 
probabilities of 50% or 25% corresponded with even smaller posterior probabilities. 
45 
C H A P T E R 4 
Discussion 
We found that a change in HDL cholesterol induced by two different diets, one low in fat and 
one high in oil, did not change flow-mediated vasodilation, one of the markers of endothelial 
function. This suggests that the reduction in HDL cholesterol by a low-fat, high-carbohydrate 
diet does not have an adverse effect on vascular functioning in individuals of the type studied 
here. 
Does a reduction in HDL cholesterol impair endothelial function? From prior to posterior 
probability 
We expected to find a smaller flow-mediated vasodilatation after the low-fat diet than after the 
high-oil diet We based this on data of our previous study and on data of studies of others. In 
our previous study, a decrease in serum HDL cholesterol of 0.36 mmol/L went together with a 
decrease in FMD of 1.8%-units. We designed the diets in the present study in such a way that a 
difference in HDL cholesterol of 0.20 mmol/L could be expected, and thus a difference in 
FMD of 0.20/0.36 xl.8%-units or 1%-units. This expectation is based on a positive, linear 
relation between HDL cholesterol and endothelial function. Indeed, many18-2934 but not all35 
cross-sectional studies showed a positive relation between serum HDL cholesterol and 
endothelial function. Another reason why we expected to see a decrease in endothelial function 
after a decrease in HDL cholesterol is that other studies showed changes in endothelial function 
when risk factors for CVD were changed. For example, lowering of elevated homocysteine by 
folic acid improved endothelial function after 6 weeks36. Also lowering of LDL-cholesterol by 
statins37^1 or diet and cholestyramine42 was shown to improve endothelial function. Based on 
these previous studies, we hypothesised that a predicted decrease in serum HDL cholesterol of 
0.2 mmol/L would lower FMD by at least 1 %-unit. We gave this hypothesis a prior probability 
of 75%, but evidently different prior probabilities may be postulated (Table 4.5). Based on our 
data, the hypothesis that a diet low in fat would decrease flow-mediated vasodilatation by the 
postulated amount became less likely; the posterior probability was only 11%. Moreover, a 
recent study in Australian men and women showed that a low-fat diet decreased serum HDL 
cholesterol but did not affect arterial elasticity when compared to a diet high in 
monounsaturated fats43. 
We did not measure HDL composition or particle size. However, it is possible that different 
diet-induced decreases in HDL cholesterol have different effects on HDL composition or 
particle size. Indeed, studies in which fat was replaced by carbohydrates show a change in the 
composition of HDL particles, with a larger decrease in the antiatherogenic HDL2 subtraction 
than in the HDL3 subtraction44-45. In contrast, replacement of saturated fat by trans fat 
decreased serum HDL cholesterol without changing the composition of the HDL particles46 
and with only a slight decrease in apolipoprotein A-I 47>48. However, these differences point at a 
more atherogenic change in HDL induced by a low-fat diet than by a diet rich in trans fatty acids, 
and this is not reflected in the changes in flow-mediated vasodilation. 
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Other factors in the diets that might have affected endothelial function 
The goal of the two study diets was to achieve a difference in HDL cholesterol while keeping 
the diets as equal as possible. Although that goal was reached, there were a number of 
differences between the diets that might have counteracted an effect of HDL cholesterol. First, 
there was a difference in fatty acid composition between the two diets because we wanted to 
keep serum LDL-cholesterol constant If we had replaced 20 en% of carbohydrates with 20 en% 
of monounsaturated fatty acids, serum LDL-cholesterol would have decreased by 0.12 
mmol/L49. Thus, the high-oil diet was higher in saturated fat (5% of energy) and 
polyunsaturated fat (2% of energy). The higher intake of saturated fat might have impaired 
endothelial function, but this is only suggested by short-term studies that compared high-fat with 
low-fat meals50'51. On the other hand, the higher intake of polyunsaturated fats might have 
improved endothelial function because these fats were shown to improve arterial compliance, 
although at higher intakes52. The mechanism by which fats might affect endothelial function is 
unclear, because not all studies show an impairment of endothelial function after a high-fat 
meal53. It is possible that high concentrations of triacylglycerols in serum cause the impairment 
because intravenous dosing of triacylglycerols results in impaired endothelial function54. 
However, others suggest that especially used fats, rich in degradation products of heated fat, may 
impair endothelial function53. Although in our study the concentration of fasting triacylglycerols 
in serum was higher after the low-fat diet than after the high-oil diet, it is unlikely that this had an 
effect on endothelial function55. 
The two diets not only differed in fat and carbohydrate content: the intake of fruits and 
vegetables was also higher on the low-fat diet than on the high-oil diet. We could have kept the 
intake of fruits and vegetables equal on the two diets, but then the amount of starchy foods, 
such as potatoes, rich and pasta, would have been too bulky to be appetizing. Thus, the intake of 
some vitamins was different between the diets. We estimate that the daily intake of folate from 
fruits and vegetables was 25-50 ug higher from the low-fat diet than from the high-oil diet56. 
Consequently56'57, serum homocysteine concentrations were slightly (0.2 umol/L) lower after the 
low-fat diet than after the high-oil diet This decrease was probably too small to have improved 
flow-mediated vasodilation36'58. Another difference between the two diets was vitamin C: the 
low-fat diet contained about 30 mg per day more vitamin C than the high-oil diet This 
difference is unlikely to have had an effect on endothelial function because studies that showed 
an effect of vitamin C used amounts of 500-1000 mg/d59-62. In contrast to vitamin C and folic 
acid, which were higher on the low-fat diet, vitamin E intake was higher on the high-oil diet, 
mainly because we used olive oil. However, vitamin E does not appear to have strong effects on 
endothelial function63 and the difference between diets was only 10 mg/day, probably too small 
to have had any effect. 
In conclusion, we showed that flow-mediated vasodilation, one of the markers of endothelial 
function, was not affected when HDL cholesterol was lowered by substituting carbohydrates for 
monounsaturated oil. Thus, our data provide no evidence for an adverse effect of low-fat diets 
on vascular functioning. 
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Consumption of a solid fat rich in lauric 
acid results in a more favorable serum 
lipid profile in healthy volunteers than 
consumption of a solid fat rich in trans 
fatty acids 
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A B S T R A C T 
Background Solid fats are used in food manufacturing to provide texture and firmness to 
foods. Such fats are rich in either saturated or trans fatty acids, which both increase risk of 
coronary heart disease. Epidemiological and experimental studies suggest that trans fatty 
acids increase risk more than saturates because they lower serum H D L cholesterol. 
However, there appear to be differences between saturates in their effect on HDL-
cholesterol. 
Aim We investigated whether consumption of a solid fat rich in lauric acid (C12:0) would 
result in a more favorable blood lipid profile than consumption of a solid fat rich in trans 
fatty acids. 
Methods We fed 32 healthy volunteers 2 controlled diets in a 2x4 weeks randomized cross-
over design. The diets consisted of a background diet supplemented with margarines. In the 
Trans-diet, 9.2% of energy was provided by trans fatty acids and 12.9% by saturated fatty 
acids. In the Sat-diet, energy intake from trans fatty acids was 0% and from saturated fatty 
acids 22.9 %. Lauric acid comprised one third of all saturates in the Sat-diet. 
Results Serum HDL-cholesterol was 0.36 mmol /L lower at the end of the Trans-diet than at 
the end of the Sat-diet (95% CI, -0.46 to -0.26) while serum LDL-cholesterol and 
triglycerides remained stable. Serum total cholesterol was 0.31 mmol /L (95% CI, -0.48 to 
-0.14) lower at the end of the Trans-diet than at the end of the Sat-diet. Consumption of a 
solid fat rich in lauric acid gives a more favorable serum lipoprotein pattern than 
consumption of partially hydrogenated soybean oil rich in trans fatty acids. 
Conclusion Solid fats rich in lauric acids, such as tropical fats, appear to be preferable to trans 
fats in food manufacturing where hard fats are indispensible. 
51 
C H A P T E R 5 
Introduction 
Margarines and vegetable shortenings are important sources of trans fatty acids in industrialized 
countries1. The intake of vegetable shortenings exceeds that of margarines and is likely to 
increase even further because of their use in ready-to-eat foods and for deep-fat frying. This is 
an undesirable development, because intake of trans fatty acids is related to increased risk of 
cardiovascular disease2-4. Experimental studies support this relation: many metabolic studies 
showed that trans fatty acids have an unfavorable effect on blood lipids because, like saturated 
fatty acids, they increase serum LDL-cholesterol5-8. Moreover, replacement of saturated by trans 
fatty acids was shown to decrease serum HDL-cholesterol in many studies9"12, which suggests an 
additional increase in risk of cardiovascular disease13-21. In a response to the negative health 
effects of trans fatty acids, many European manufacturers have decreased the trans fatty acid 
content of most stick margarines to amounts of less than 2% of energy22-23. The trans fatty acid 
content can be decreased by reducing the degree of hydrogenation, which results in softer 
margarines. Alternatively, solid margarines can be produced from tropical fats instead of from 
partially hydrogenated vegetable oils: the amount of saturated fatty acids will then be higher but 
the amount of trans fatty acids will be negligible22. 
Studies suggest that replacement of 10% of energy from trans fat by saturated fat will increase 
serum HDL-cholesterol by 0.15 mmol/L7-24. However, this prediction is based on studies in 
which palmitic acid is the major saturated fatty acid, and some, although not all10, studies suggest 
that lauric acid might increase serum HDL cholesterol more than palmitic acid7-25. Palm kernel 
fat and coconut fat are rich sources of lauric acid (USDA Nutrient Database for Standard 
Reference, Release 13). We investigated whether replacement of a margarine rich in trans fatty 
acids by a margarine rich in lauric acid would produce a stronger increase in serum HDL-
cholesterol than the 0.15 mmol/L per 10 en% that was estimated before. 
Methods 
The protocol of the study was approved by the Medical Ethical Committee of Wageningen 
University. We gave each volunteer a written and oral presentation of the purpose and execution 
of the studies. Each volunteer signed an informed consent form. 
Subjects 
We enrolled 11 men and 21 women with a mean age of 30 years (range, 18 to 69 years) in the 
study. All of the volunteers were non-smokers and all were healthy as assessed by means of a 
medical questionnaire. Their initial serum cholesterol was 5.0 mmol/L (range, 3.0 to 7.1 
mmol/L); their body mass index 22.8±2.5 kg/m2. The volunteers had no history of any chronic 
illness and were not taking any medication known to affect blood lipid metabolism. They all 
completed the study. 
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Study design 
We provided 2 controlled diets for 4 weeks each in a randomized cross-over design. One diet 
was rich in trans fatty acids (Trans) and one was diet rich in saturated fatty acids (Sat). There was 
no wash-out period between the two diets. The two diets were equal except for supplemental 
margarines, and were given in a 28-day menu cycle. The background diet consisted of 
conventional food items. 
The margarine that was used in the diet rich in trans fatty acids was a blend of 70 parts of 
partially hydrogenated soy oil, containing 44% trans-C\8:l (Gouda's Glorie, Van Dijk Foods, 
Lopik, the Netherlands); 14 parts of a vegetable oil containing 63% linoleic acid and 23% oleic 
acid (Becel, Unilever, Vlaardingen, the Netherlands) and 16 parts of water (Table 5.1). The 
margarine that was used in the diet rich in saturated fat was a blend of 60 parts of palm kernel 
fat (Loders Croklaan, Wormerveer, the Netherlands) and 40 parts of commercially available 
margarine made from a blend of unhydrogenated rapeseed oil, soybean oil, sunflower oil, palm 
kernel fat, coconut oil, and palm oil (Blue Band, Van den Bergh BV, Rotterdam, the 
Netherlands) (Table 5.1). 
Table 5.1 fatty acid composition (g/100 g fatty acid ) of the margarines 
used in the diet rich in trans fatty acids and in the diet rich in saturated fatty 
acids 
Fatty Acid 
Saturated 
Laurie acid (C12:0) 
Myristic acid (C14:0) 
Palmitic acid (C16:0) 
Stearic acid (C18:0) 
Monounsaturated 
c/s-Monounsatu rated 
frans-Monounsaturated 
Polyunsaturated 
Linoleic acid (c/s,c/s-C18:2) 
Unknown 
Trans margarine 
30.5 
not detected 
0.1 
10.5 
18.5 
59.5 
18.6 
40.91 
8.7 
8.2 
1.3 
Sat margarine 
63.1 
24.5 
10.2 
17.0 
7.4 
21.3 
20.9 
0.3 
15.0 
14.6 
0.6 
1
 All frans-monounsaturated fatty acids were frans-C18:1 
Both supplemental margarines were produced at NIZO Food Research (Ede, the Netherlands). 
The margarines were used as a spread, as shortening in bread and cookies, and as fat in sauce 
and gravy. They supplied 77% of total fat in the Trans-diet and 68% of total fat in the Sat-diet. 
The composition of the experimental diets was calculated using food composition tables26-28. To 
check the composition of the diets we collected duplicates of all meals (Table 5.2). The analyzed 
values were similar to the calculated composition. 
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We designed menus for 14 levels of energy intake, ranging from 7 to 20 MJ per day. The 
subjects were allocated to an energy intake level close to their habitual energy intake, which was 
estimated from a food frequency questionnaire. We provided 90 percent of energy; all food was 
weighed out for each subject. The remaining 10 percent of energy had to be chosen from a list 
of low-fat food items. Subjects recorded their choice from this low-fat food list in a diary. 
Monday through Friday of each week subjects ate a hot meal under our supervision. All other 
foods (bread; margarine; meat and/or cheese; honey, jam, or sprinkles; fruit; milk and/or yogurt) 
were packaged for consumption at home, as was food for the weekends. They received the diets 
for 21-32 days (mean 27.5 days). 
We weighed the subjects twice a week and increased or decreased their energy intakes as 
needed to maintain stable body weights. 
Table 5.2 Analyzed composition of the two experimental diets 
Fatty Acid 
Carbohydrate (energy%) 
Protein (energy%) 
Total fat (energy%) 
Saturated 
Laurie acid (C12:0) 
Myristicacid(C14:0) 
Palmitic acid (C16:0) 
Stearic acid (C18:0) 
Monounsaturated, total 
c/s-C18:1 
fra/7S-C18:1 
total trans 
Polyunsaturated 
Linoleic acid (c/s,cv's-C18:2) 
Linolenic acid (c/s,c/s,c/s-C18:3) 
Cholesterol (mg/MJ) 
Cholesterol (mg/day) 
Fibre (g/MJ) 
Fibre (g/day) 
Energy (MJ/day) 
Energy (kcal/day) 
Trans-diet 
48.6 
14.0 
37.4 
12.9 
0.3 
0.8 
5.7 
5.3 
18.2 
8.4 
9.2 
9.4 
4.7 
4.1 
0.3 
27.0 
248.4 
3.2 
29.4 
9.20 
2199 
Sat-diet 
45.6 
13.5 
41.0 
22.9 
6.8 
3.8 
7.8 
3.1 
8.8 
7.9 
0.3 
0.4 
6.9 
5.9 
0.7 
26.8 
253.5 
3.1 
29.3 
9.46 
2261 
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Biochemical analysis 
We took blood samples on two separate days after day 19 of each diet All 4 blood samples of 
each subject were analyzed in duplicate within 1 run. Total cholesterol and triglycerides 
(Cholesterol Flex™ and Triglycerides Flex™ reagent cartridge, Dade Behring, Newark USA) 
and HDL cholesterol {liquid N-geneous™ HDL-C assay, Instruchemie BV, Hilversum, the 
Netherlands) were measured, and LDL-cholesterol was calculated with the Friedewald-formula. 
The coefficient of variation of 64 duplicate measurements was 0.4% for total cholesterol, 1.5% 
for triglycerides, and 1.1% for HDL cholesterol. 
The fatty acid composition of the margarines and the experimental diets was analyzed by gas-
liquid chromatography (GLC) of the fatty acid methyl esters (FAME) (Metcalfe 1966) and, for 
18 carbon trans fatty acids, by GLC of fatty acid 4,4-dimethyloxazoline (DMOX) derivatives29. 
Statistics 
We averaged the duplicate measurements in each dietary period and then calculated for each 
subject the difference between diets. We tested whether these differences were significandy 
different from zero by the Student / test for paired samples. We give two-sided 95% confidence 
intervals for the differences. 
Results 
Body weight and compliance to study protocol 
Changes in body weight during the study were small and non-significant: -0.4+0.9 kg during the 
Trans-diet and -0.6±0.9 kg during the Sat-diet (P value for difference between diets >0.5). We 
checked the diaries for deviations from the study protocol but only minor deviations, unlikely to 
interfere with the results of the study, had been reported. 
Blood lipids 
Total cholesterol was 0.31 mmol/L (95% CI, 0.14 to 0.48 mmol/L, P=0.0007) or 12.0 mg/dL 
lower at the end of the Trans-diet period than at the end of the Sat-diet period (Figure 5.1). This 
difference was mainly due to a difference in HDL-cholesterol, which was 1.89+0.46 mmol/L 
(73.1 ±17.8 mg/dL) at the end of the Sat-diet and 1.4610.33 mmol/L (56.5112.8 mg/dL) at the 
end of the Trans-diet, a difference of 0.36 mmol/L (95% CI, 0.26 to 0.46, P<0.0001) (Figure 
5.1). Serum LDL-cholesterol did not differ between the diets and was 3.0510.81 mmol/L at the 
end of the Sat-diet and 3.0410.80 mmol/L at the end of the Trans-diet (P=0.64). Serum 
triglycerides were slightly lower at the end of the Sat-diet, with a concentration of 0.9010.36 
mmol/L, than at the end of the Trans-diet, when the concentration was 0.9810.41 mmol/L 
(P=0.66) (Figure 5.1). 
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Figure 5.1: 
Differences in fasting 
lipoproteins and lipids in 32 
fasting subjects when 9.2 
en% of trans fatty acids in 
the diet were replaced by 
saturated fatty acids. Bars 
represent means with 
SEM. To convert values for 
total, HDL, and LDL 
cholesterol to mg/dL, 
multiply by 38.67. To 
convert triglycerides to 
mg/dL, multiply by 88.54 
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The order of the two diets hardly affected the change in HDL cholesterol: the mean change was 
0.33 ±0.26 mmol/L in subjects who went from the Trans-diet to the Sat-diet and 0.39+0.31 
mmol/L in the subjects who received the diets in the reverse order (P=0.5). 
The LDL:HDL ratio was significantly higher after the Trans diet, with a ratio of 2.2, than 
after the Sat diet, when the ratio was 1.8 (difference -0.41, 95% CI -0.54 to -0.27, P<0.0001). 
Discussion 
We investigated whether replacement of a margarine rich in trans fatty acids by a margarine rich 
in lauric acid would produce a stronger increase in serum HDL-cholesterol than the 0.15 
mmol/L per 10 en% that was estimated before30. Indeed, serum HDL-cholesterol was 0.36 
mmol/L higher at the end of a 4-week period in which 9.2% of energy was provided by trans 
fatty acids and 12.9% by saturated fatty acids than after a 4-week period in which energy intake 
from trans fatty acids was 0% and from saturated fatty acids 22.9 %. Although the diets did not 
provide equal amounts of polyunsaturated fatty acids (a difference of 2.2% energy), this 
difference could only account for about 0.015 mmol/L in HDL cholesterol, using the Mensink 
and Katan (1992) equation. Thus, lauric acid or C12:0 appears to increase serum HDL-
cholesterol more than myristic or C16:0 and palmitic acid or C14:07'12-25. The major trans fatty 
acids in our study were the n-10, n-9, and n-11 isomers of C18:l, as is usual in partially 
hydrogenated soybean oil. These trans fatty acids were also the major trans fatty acids that used in 
many other studies5'6'11'31. 
The difference in serum HDL-cholesterol at the end of the two diets is in line with results of 
epidemiological studies that suggest that risk of cardiovascular disease is increased more by 
consumption of trans fatty acids than by consumption of saturated fatty acids1. For example, in 
the Health Professionals follow-up study the multivariate relative risk for myocardial infarction 
was 1.12 (95% CI, 0.97 to 1.28) for each 5% increase in intake of saturated fatty acids and 1.36 
(95% CI, 1.03 to 1.81) for each 2% increase in intake of trans fatty acids32. In the Nurses' Health 
Study, intake of foods rich in trans fatty acids, such as margarines, was also significantly 
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associated with higher risk of coronary heart disease2. In the same study, each increase of 5% of 
energy intake from saturated fat was associated with a multivariate relative risk of 1.17 (95% CI, 
0.97 to 1.41) of coronary heart disease. This was less than the relative risk associated with a 2% 
increase of energy intake from trans fatty acids, which was 1.93 (95% CI, 1.43 to 2.61) 4. These 
studies show that the intake of saturated and especially trans unsaturated fatty acids should be 
reduced in order to reduce the risk of coronary heart disease. Moreover, we found that the 
LDL:HDL ratio was signifkandy higher after the diet rich in trans fatty acids than after the diet 
rich in saturated fatty acids, indicating a higher risk of coronary heart disease. 
The consumption of saturated fat and trans fat should not be encouraged. However, in 
products that need solid fats for their texture or firmness, replacement of trans fat by solid, 
tropical fats rich in lauric acids appears to be prudent 
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Replacement of dietary saturated fat 
with trans tt. reduces serum 
paraoxonase activity in healthy men and 
women 
N.M. de Roos, E.G. Schouten, L.M. Scheek, A. van Tol, M.B. Katan 
Submitted 
A B S T R A C T 
Background A high intake of saturated fat and of trans isomers of unsaturated fat is 
associated with increased risk of cardiovascular disease. 
Methods Recently we found that replacement of saturated fat by trans fat in a dietary 
controlled study with 32 volunteers decreased serum H D L cholesterol and impaired 
endothelial function, suggesting that trans fats have stronger adverse effects than saturated 
fats. To investigate this further, we measured the activity of paraoxonase (PON1) in serum 
after both diets, because P O N 1 protects lipoproteins from oxidative damage and higher 
P O N 1 activity appears to be related to lower cardiovascular disease risk. 
Results P O N 1 activity was 195.9 U / L after 4 weeks of a diet with 22.9% of energy (en%) 
from saturated fat and decreased to 184.5 U / L when 9.3 en% from saturated fat was 
replaced by trans fat (P=0.006). 
Conclusion Replacement of dietary saturated fat by trans fat not only decreased serum H D L 
cholesterol and impaired endothelial function, but also decreased the activity of serum 
paraoxonase. 
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Introduction 
Intake of trans and saturated fatty acids is associated with increased risk of cardiovascular 
disease1, probably because of their effects on serum lipoproteins. Trans fatty acids increase serum 
low-density lipoprotein (LDL) cholesterol to a similar extent as saturated fatty acids. In addition, 
they decrease serum high-density lipoprotein (HDL) cholesterol29, resulting in a undesirably 
high LDL:HDL ratio. 
In a recent study10 we compared the effects of saturated and trans fatty acids on serum HDL-
cholesterol and endothelial function in a controlled dietary intervention. Endothelial function 
was assessed as flow-mediated vasodilation of the brachial artery, a non-invasive marker for 
coronary artery disease risk11. We found that serum HDL-cholesterol was 20% lower on the diet 
rich in trans fatty acids and that flow-mediated vasodilation was impaired. Serum concentrations 
of LDL-cholesterol and triglycerides remained constant It is probable that the decrease in 
HDL-cholesterol paralleled a decrease in the concentration of high-density lipoproteins in 
serum, because trans fatty acids have also been shown to decrease the concentration of 
apolipoprotein A-I, the major protein of HDL, in serum4-8. HDL can inhibit the formation of 
oxidized LDL in vitro1215, and LDL isolated from subjects with low HDL concentrations 
appears to be more susceptible to oxidation than LDL isolated from subjects with high HDL 
concentrations in serum16. In subjects whose LDL is more susceptible to oxidation, endothelial 
function appears to be impaired16. Thus, a decrease in HDL might result in impaired endothelial 
function through its antioxidant effect on LDL. 
The antioxidant capacity of HDL is thought to be largely1719 although not entirely15 effected 
by paraoxonase-1 (PON1), an esterase which is closely attached to the HDL-particle. PON1 was 
shown to catalyze hydrolysis of lipid peroxides in oxidized lipoproteins17. The activity of serum 
PON1 is genetically determined19, but can be influenced by changes in the diet20"23 and 
smoking24. There are several indications that serum PON1 activity is associated with 
cardiovascular disease. First, PONl-knockout mice are more susceptible to atherosclerosis than 
their wild type littermates25. This is in accordance with several epidemiological studies showing 
that cardiovascular disease patients have lower serum PON1 activity or concentrations than 
healthy controls19. In addition, a transgenic mouse model carrying the human PON1 gene 
showed higher PONl-concentrations and less atherosclerosis than the wild type after feeding 
both types of mice an atherogenic diet for 16 weeks26. There is also some evidence that PON1 
polymorphisms are associated with cardiovascular disease19. For example, a prospective study 
among participants in the Kuopio ischemic heart disease risk factor study showed that men who 
were MM homozygous for the Met54Leu polymorphism had a more than threefold risk of a 
first myocardial infarction than men who were LL homozygous27. 
We hypothesized that a diet rich in trans fatty acids that lowers serum HDL-cholesterol would 
also decrease PON1 activity in serum. We tested this in the same study for which we previously 
reported serum lipoproteins and flow-mediated vasodilation (Chapter 3). 
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Subjects and Methods 
The study was approved by the Medical Ethics Committee of Wageningen University. Each 
volunteer signed an informed consent form after oral and written explanation of the study. 
Design 
We performed a dietary controlled study with a 2x4 weeks cross-over design. Subjects were 11 
men and 21 women aged 18 to 69 years who were free of cardiovascular or kidney disease and 
who were not taking any drugs known to alter lipid metabolism. At baseline their mean fasting 
serum cholesterol was 5.1+1.1 mmol/L and triacylglycerols 1.3±0.6 mmol/L. Serum lipids, 
flow-mediated vasodilation, and serum paraoxonase activity were measured at the end of the 4-
week diet periods. Other details of the study may be found elsewhere (Chapter 3). 
Diets 
The two controlled diets consisted of regular foods supplemented with special margarine. We 
used the margarine to obtain a difference in trans and saturated fatty acids of about 10% of 
energy. We collected duplicate diets for analysis of macronutrients. The diet rich in trans fat 
contained 48.6 en% of carbohydrates, 14.0 en% of protein, and 37.4 en% of fat, with 9.3 en% 
from trans fatty acids and 12.9 en% from saturated fatty acids. The diet rich in saturated fat 
contained 45.6 en% of carbohydrates, 13.5 en% of protein, and 41.0 en% of fat, with 0.3 en% 
from trans fatty acids and 22.9 en% from saturated fatty acids. Body weight was kept stable 
throughout the study. 
Analyses 
Blood was collected after an overnight fast in evacuated collection tubes (Venoject II, Terumo, 
Leuven, Belgium) from an antecubital vein and allowed to clot for 30 minutes at room 
temperature. Serum was obtained by centrifugation at 1187xg for 10 minutes at 4°C. To 
eliminate inter-assay variation, serum was stored at —75°C and all analyses were done at the end 
of the study. PON1 activity was determined using paraoxon as a substrate at pH 8.0 20. PON1 
activity was expressed in U/L, which is equal to 1 |amol of hydrolyzed paraoxon/L/min. 
Statistics 
We used the average of 2 repeated measurements of serum HDL-cholesterol and 1 
measurement of PON1 activity in serum for statistical analysis. Differences between the diets 
were tested for normality using the Kolmogorov-Smirnov test 28. We give means with 95% 
confidence intervals of the change between the two diets. In addition we used the one-sample t 
test to test whether changes were significandy (P<0.05) different from zero and we calculated 
the Pearson correlation coefficient between changes in HDL-cholesterol and changes in serum 
paraoxonase activity. We used GraphPad Prism (version 3.0 for Windows) for statistical analyses 
and graphs (GraphPad Software, Inc., San Diego, U.S.A.). 
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Results 
Mean PON1 activity was 184.5 U/L on the diet rich in trans fatty acids and 195.9 U/L on the 
diet rich in saturated fatty acids (P=0.006). The difference between the two diets was 11.5 U/L 
(95% CI: 3.6 to 19.3) or 6%. The effect was consistent in 26 of the 32 subjects PON1 activity 
was lower on the trans fat diet than on the saturated fat diet 
Serum HDL-cholesterol was 1.49 mmol/L (57.6 mg/dL) on the diet rich in trans and 1.85 
mmol/L (71.5 mg/dL) on the diet rich in saturated fatty acids, while other serum lipids 
remained constant (Table 6.1). As shown in Figure 6.1, changes in HDL-cholesterol correlated 
with changes in PON1 activity (r=0.47, 95% CI: 0.15 to 0.71). We did not find a significant 
correlation between changes in PON1 activity and changes in the percentage flow-mediated 
vasodilation (r=-0.18, 95% CI: -0.5 to 0.2). 
Table 6.1 Serum lipoproteins and lipids (mmol/L1) of the 32 volunteers at the end 
of the 4-week controlled diets. We show means±SD for each diet and the mean 
with 95% CI for the difference between the two diets 
Total cholesterol 
HDL-cholesterol 
LDL-cholesterol 
Triacylglycerols 
Diet rich in 
saturated fat 
5.32 ± 0.92 
1.85 ±0.46 
3.04 ± 0.78 
0.94 ± 0.51 
Diet rich in 
trans fat 
5.01 ± 0.92 
1.49 ±0.33 
3.07 ± 0.79 
0.97 ±0.41 
Difference (95% CI) 
0.31 (0.14 to 0.48) 
0.36 (0.26 to 0.46) 
-0.03 (-0.18 to 0.12) 
-0.03 (-0.18 to 0.11) 
1
 To convert mmol/L to mg/dL multiply by 38.67 for total, HDL and LDL cholesterol and 
multiply by 88.57 for triacylglycerols 
Figure 6.1. 
Correlation between 
changes in HDL-cholesterol 
and changes in paraoxonase 
activity in serum. Positive 
changes indicate higher 
values on the diet rich in 
saturated fatty acids. 
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Discussion 
A diet rich in trans fatty acids resulted in a significantly lower PON1 activity towards paraoxon 
than consumption of a diet rich in saturated fatty acids. This lower enzyme activity might explain 
the impaired endothelial function we observed previously in the same population after 
consumption of the diet rich in trans fatty acids. 
The size of the effect (6%) was similar to that of alcohol consumption compared to water 
consumption 20 and about half the difference reported between smokers and non-smokers 24. In 
these studies the 'high-risk' categories {trans fat, water, smoking) had lower serum paraoxonase 
activities. 
It is still unclear whether the activity of PON1 towards paraoxon is a good marker of the 
physiological function of the enzyme 29. Evidence in favor of this was given by a case-control 
study that showed that PON1 activity towards paraoxon was significantly lower in 106 male 
cardiovascular disease patients than in 106 age-matched controls 30. Also, a study of patients with 
familial hypercholesterolemia showed that increases in PON1 activity after simvastatin therapy 
resulted in lower lipid peroxide concentrations in serum 31. Thus, an increase in the activity of 
serum PON1 towards paraoxon appears to reflect a physiological reduction in lipid peroxides 
and could therefore act as a marker of lipid peroxidation. 
We were not able to show a relation between changes in paraoxonase activity and changes in 
flow-mediated vasodilation in our subjects. However, our study was not powered to find such a 
relation, and the confidence interval for the correlation coefficient was therefore wide. Others 
have found that serum paraoxonase activity was correlated with endothelial function in 27 
patients with angiographically confirmed atherosclerosis: the percentage constriction following a 
serotonin provocation test was smaller in patients with higher paraoxonase activity towards 
paraoxon 32. 
In conclusion, we showed that consumption of trans fatty acids, which is related to increased 
risk of coronary heart disease, decreased serum PON1 activity. A decreased activity of this 
enzyme might result in increased concentration of lipid peroxides in serum, which could impair 
vascular functioning. This effect could be part of the mechanism by which trans fatty acids exert 
adverse effects on coronary heart disease risk. 
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Trans monounsaturated fatty acids and 
saturated fatty acids have similar effects 
on postprandial flow-mediated 
vasodilation 
N.M. de Roos, E. Siebelink, M.L. Bots, A. van Tol, E.G. Schouten, M.B. Katan 
A B S T R A C T 
Background Consumption of trans fatty acids is associated with increased risk of coronary 
heart disease (CHD). We previously showed that replacement of saturated fatty acids by trans 
fatty acids impaired flow-mediated vasodilation (FMD), a marker of CHD risk. In that study, 
FMD was measured in fasting subjects. We wanted to investigate whether the same 
impairment would be seen after a single meal. 
Objective To study the postprandial effects of meals rich in saturated fatty acids or trans fatty 
acids on flow-mediated vasodilation. 
Methods We fed 25 healthy men two different testmeals with 0.9-1.0 g fat/kg bodyweight: 
one rich in saturated fatty acids (Sat), mainly from palm kernel fat, and one rich in trans fatty 
acids (Trans) from partially hydrogenated soy bean oil. 
Results FMD increased from a fasting value of 2.3±2.0% of the baseline diameter to 
3.0±1.7% after the Sat-testmeal (95% CI for change -0.33, 1.70) and from 2.7±2.3% to 
3.1 ±2.0% after the Trans-testmeal (95% CI for change -0.57, 1.29). Differences between 
testmeals were not significant. Serum triacylglycerols increased by 0.46±0.36 mmol/L after 
the Sat-testmeal and by 0.68±0.59 mmol/L after the Trans-testmeal; a difference of 0.23 
(0.07, 0.39) mmol/L. Serum HDL-cholesterol was hardly affected by the testmeals. The 
activity of serum paraoxonase, an esterase bound to HDL, increased slightly after the two 
test meals but the difference between meals was not significant. 
Conclusion FMD was not impaired and not different after test meals with saturated or trans 
fatty acids. Thus, differences in long-term effects of these fats are not caused by differences 
in acute effects on the vascular wall. 
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Introduction 
Consumption of a diet rich in trans fatty acids, found in fried fast foods, bakery goods, potato 
chips, french fries, and solid margarines, is associated with increased risk of coronary heart 
disease (CHD)1. Pooled data from prospective follow-up studies suggest that each 2% increase 
in energy intake from trans fatty acids is associated with a 25% increase in risk2. This increase in 
risk is higher than that for a 2% increase in energy intake from saturated fats1, although their 
effect on LDL-cholesterol is similar. The difference in risk could be caused by effects on HDL-
cholesterol, which is decreased when saturated fats are replaced by trans fats3-4. We used 
metabolic studies with flow-mediated vasodilation as primary endpoint to study the causal role 
of HDL-cholesterol in coronary heart disease. Flow-mediated vasodilation is the percentage 
increase in arterial diameter after provoked increases in blood flow; impaired dilation appears to 
be an early stage of atherosclerosis5. Moreover, an impaired flow-mediated vasodilation has been 
related to increased risk of recurrence of cardiovascular events in 73 patients with chest pain6. 
In the first study done at our lab we showed that replacement of «9% of energy from 
saturated fat by trans fat decreased serum HDL-cholesterol by 0.39 mmol/L and impaired flow-
mediated vasodilation (Chapter 3). This result was in line with the observation that trans fatty 
acids are more strongly related to cardiovascular disease than saturated fatty acids, and suggested 
that this was caused by the decrease in HDL-cholesterol. We verified the effect of a decrease in 
HDL-cholesterol in a subsequent study with a low-fat versus a high-oil diet, but this time flow-
mediated vasodilation was not impaired by the decrease in HDL-cholesterol (Chapter 4). This 
result appeared to weaken the evidence for a causal role of HDL-cholesterol but we may have 
missed an effect, because the decrease in HDL-cholesterol was half of that observed in our first 
study. 
We performed the present study to investigate whether differences in effect of trans and 
saturated fatty acids might be independent of HDL-cholesterol. We postulated that the increased 
risk with consumption of trans fatty acids might be due to acute effects of circulating trans fatty 
acids in serum. Indeed, it has been shown by others that consumption of fat-enriched meals 
impairs flow-mediated vasodilation (Table 7.1), but we found no data on effects of trans fatty 
acids. Therefore we compared the effects on flow-mediated vasodilation of a testmeal with trans 
fatty acids with those of a testmeal with saturated fatty acids. We also measured the activity of 
the HDL-associated enzyme paraoxonase, an esterase related to cardiovascular disease risk. We 
had found earlier that replacement of saturated fatty acids by trans fatty acids reduced the activity 
of this enzyme (Chapter 6). A high serum paraoxonase activity prevents oxidation of lipids in 
LDL in vitro7; if this occurs in vivo paraoxonase might improve vascular function8. We 
hypothesized that the activity of serum paraoxonase would parallel changes in flow-mediated 
vasodilation. 
Subjects and methods 
The study was approved by the Medical Ethics Committee of Wageningen University. All 
subjects signed an informed consent form. 
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Table 7.1 Postprandial effects (3-4 h after a meal) of oral fat loads on flow-mediated 
vasodilation in men (m) and women (w). 
subjects 
16m 
5m, 5w 
13 
10m 
7w, 5m 
7m, 13w 
test meals 
2 isocaloric meals: 
low-fat (5 g fat) vs high-oleic acid (50 g fat) 
2 isocaloric meals: 
low-fat (0 g fat) vs. high-fat (50 g fat, 14 g 
saturated). Low-fat ±90 mg more vitamin C 
2 isocaloric high-fat fast-food meals 
rich in saturated and trans fatty acids 
1 high-fat meal (65g/m2 body surface area) 
saturated fat 
1 fat tolerance test (1480 kcal, 80 g saturated fat) 
4 isocaloric meals: 
low-fat (0 g fat) and high-fat (50 g fat, 14 g 
change from fasting 
decrease 
decrease 
decrease 
decrease 
decrease 
decrease, but not 
with added vitamins 
ref 
13 
14 
20 
17 
31 
19 
no decrease after 26 
unused fat; decrease 
after used fat 
no effect 
saturated) with or without vitamins C and E 
10m 3 meals (milkshakes): 1 control (low-fat) and 2 
with 46 g extra fat (saturated), either unused or 
used for deep-fat frying 
12 2 isocaloric meals (1030 kcal, 61 g fat): saturated 
fatty acids versus monounsaturated fatty acids 
10m 5 isocaloric meals (900 kcal, 50 g fat): 
olive oil (+/- vitamins C, E or vegetables), canola 
oil, salmon 
25m, 25w 3 isocaloric meals high in fat (mainly saturated fat) small increase 
30 
decrease after olive 23 
oil only 
29 
Subjects 
We recruited 40 non-smoking men aged >35 y by advertising in local papers and by inviting 
subjects who had taken part in previous studies. We excluded 9 men because of diabetes, 
thrombosis, or use of cholesterol-lowering drugs. -All 31 remaining subjects had normal urinary 
glucose and protein (<0.3 g/L) concentrations. Five men were excluded because of high serum 
cholesterol (>8 mmol/L) and/or fasting triacylglycerols (>3 mmol/L), because we wanted to 
exclude men with an impaired lipid metabolism. Of the remaining 26 subjects 25 completed the 
study. Pre-study mean (±SD) serum cholesterol of these 25 men was 5.8+0.8 mmol/L, 
triacylglycerols 1.2±0.7 mmol/L, bodyweight 83.5±10.0kg and body mass index 
25.4±2.6 kg/m2. Their habitual diet, assessed by a validated questionnaire9, contained 11 MJ/d 
(2620 kcal/d) with 40.4% of energy (%en) from fat (saturated fat 14.9 en%). Habitual daily 
intake of cholesterol was 274 mg/d. 
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Study design 
The two test meals were served in random order on separate days within one week; this was 
repeated in reverse order the next week to obtain duplicate measurements. Thus, we had a total 
of four test days, separated by at least 1 d. 
A test day was preceded by a controlled evening meal and an overnight fast. The evening 
meal was prepared by us and packaged for consumption at home. Subjects consumed on 
average 3047kJ with this evening meal, with 20.5en% from fat (9.5en% saturated fat), 22.9en% 
from protein, and 56.5en% from carbohydrates. They were asked to refrain from sports 
activities on the day preceeding the test day and in the morning before the measurements. 
In the morning, after an overnight fast, subjects came to our lab between 7:00 and 9:30am; 
the appointment time was kept constant for each subject throughout the study. Some subjects 
came by bike, others by car; so we had everyone rest for at least 10 minutes before the start of 
the measurements. After subjects had rested, we measured flow-mediated vasodilation and took 
blood samples. Then, subjects were given the test meal which had to be consumed within 15 
minutes. Postprandial measurements were done 3 h after the end of the test meal. Subjects were 
not allowed food or drink between test meal and postprandial measurements, and were asked to 
refrain from strenuous physical activities. 
Test meals 
The two test meals differed only in source of fat. The fat used in the saturated fat meal was 
derived mainly from palm kernel fat, and was rich in lauric acid (C12:0) and myristic acid 
(C14:0); the fat used in the trans fat meal was mainly partially hydrogenated soy bean oil rich in 
trans monoenes with 18 carbon atoms (Table 7.2). 
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Table 7.2 Fatty acid composition (g/1 OOg fatty acids) of the fat rich in 
saturated fatty acids and the fat rich in trans fatty acids 
fat rich in saturated fat fat rich in trans fat 
fatty acid composition, % 
0.0 
0.0 
0.0 
0.1 
9.5 
16.8 
25.5 
33.8 
11.9 
C8:0 caprylic acid 
C10:0capricacid 
C12:0lauricacid 
C14:0 myristicacid 
C16:0 palmitic acid 
C18:0 stearic acid 
C18:1 cis 
C18:1 trans* 
C18:2 cis,cis linoleic acid 
1.9 
2.2 
39.6 
16.3 
13.3 
4.2 
12.0 
0.4 
8.6 
f
 only those with >1 % of mass in one of the test fats 
* mainly (n-10), (n-9), and (n—11) 
Table 7.3 Macronutrient composition and vitamin content of average 
portions of the two test meals 
Energy (kJ)" 
Protein (g) 
Fat(g) t 
Carbohydrate (g) 
Mono- and disaccharides (g) 
Polysaccharides (g) 
Fibre (g) 
milkshake+bread 
(21 subjects) 
4947 (1178 kcal) 
16 
79 
102 
59 
43 
7 
porridge 
(4 subjects) 
4103 (977 kcal) 
14 
82 
49 
23 
26 
3 
the average portion of porridge was smaller because subjects who consumed the 
porridge were lighter 
f
 1 % dairy fat and 99% test fats (rich in either saturated or trans fat) 
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Flow-mediated vasodilation of the brachial artery 
We measured flow-mediated vasodilation of the brachial artery, a non-invasive technique using 
ultrasound, as set up by Celermajer et al10. The ultrasound images were made with a linear array 
transducer (range 8-14 MHz) of an Esaote AU5 scanner (Pie Medical Benelux B.V., Maastricht, 
the Netherlands). All images were stored on super-VHS videotapes for off-line analysis. We 
inflated a cuff around the forearm to a pressure of 240 mmHg to induce ischemia for 5 min. 
Changes in brachial artery diameter at the site of the antecubital crease were recorded for 5 
minutes after cuff release. The maximum diameter that was reached within 5 minutes was used 
to calculate the percentage flow-mediated vasodilation from the baseline diameter. Other details 
can be found elsewhere (Chapter 2). 
The images were analyzed with special software developed by the Wallenberg Institute of 
Cardiovascular Research and the Chalmers University of Technology (Gothenburg, Sweden)11 at 
the Vascular Imaging Center of the University Medical Center in Utrecht Of the 200 
measurements (25 subjects measured 8 times each) 31 (16% of total) had insufficient quality due 
to movement of the arm or, because we had recorded a vein instead of an artery in 1 case. To 
calculate within-subject variability we used the 4 pre-meal measurements of each subject's resting 
diameter, maximum diameter, and FMD. At a mean resting diameter of 4.763 mm, the SD 
within-subjects was 0.311 mm and the corresponding CV 6.5%. The maximum diameter was 
4.883 mm, SD within-subjects 0.330 mm and the corresponding CV 6.8%. Pre-meal FMD was 
2.58% of the baseline diameter; the SD within-subjects was 2.18%-points and the corresponding 
CV was 84% of the mean FMD. The within-subject variability of the FMD was larger than the 
50-60% in our previous studies but this was due to a smaller FMD, not to a larger SD. 
Measurement of serum triacylglycerols and lipoproteins 
Blood was collected in evacuated collection tubes (Venoject II, Terumo, Leuven, Belgium) from 
an antecubital vein and allowed to clot for 30-45 minutes at room temperature. Serum was 
obtained by centrifugation at 1187xg for 10 minutes at 4 °C. To eliminate inter-assay variation, 
serum was stored at —75 °C and all analyses were done in one assay at the end of the study. 
Total cholesterol and triacylglycerols (Cholesterol Flex™ and Triglycerides Flex™ reagent 
cartridge, Dade Behring, Newark USA) and HDL cholesterol (liquid N-geneous™ HDL-C 
assay, Instruchemie BV, Hilversum, the Netherlands) were measured in one run, and LDL-
cholesterol in fasting samples was calculated with the Friedewald formula. The analytical within-
run coefficient of variation for all analyses was <1.5%. 
Measurement of serum paraoxonase activity 
Serum paraoxonase activity was measured in the serum samples of the first study week, so for 
each subject we had 1 pre-meal (fasting) and 1 postprandial sample per type of fat. PON1 
activity was determined using paraoxon as a substrate at pH 8.012. Serum paraoxonase activity 
was expressed in U/L, which is equal to 1 umol of hydrolyzed paraoxon/L/min. 
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Statistics 
We calculated for each person the mean of the 2 brachial artery measurements per type of fat 
We used SAS for statistical tests and calculations (SAS Institute Inc., Cary, NC, USA) and 
GraphPad Prism for graphing the data. 
Results 
Serum triacylglycerol concentrations were significantly increased from baseline at 3.5h after 
consumption of the test meals (Table 7.4), with a 0.23 mmol/L stronger increase after trans fat 
than after saturated fat (95% confidence interval (CI) for difference 0.07 to 0.39). The 
concentration of serum HDL-cholesterol increased slightly after consumption of the meal rich 
in saturated fat but not after the meal rich in trans fat; with a slight but statistically significant 
difference of -0.03 mmol/L between meals (95% CI, -0.06 to 0.008). The increase in serum 
total cholesterol was not significantly different between the two meals. 
The results for the brachial artery measurements are based on 21 subjects of whom we had 
paired fasting and postprandial measurements for both meals. Consumption of the test meals 
had little effect on the baseline diameter of the brachial artery, i.e. the diameter before occlusion; 
differences between fasting and postprandial diameters and between the two types of fat were 
small (Table 7.4). The maximum diameter that was reached after cuff release was larger after the 
meals than before, and the effect was similar for both types of fat Thus, the absolute increase in 
mm was larger postprandially for both types of fat, as was the percentage flow-mediated 
vasodilation. The type of fat did not affect any of the changes in brachial artery dimensions. 
Changes in serum triacylglycerols were significantly correlated with changes in flow-mediated 
vasodilation after the Sat-meal (Pearson r-0.45, 95% CI, -0.73 to -0.03) but not after the Trans-
meal (Pearson r-0.06, 95% CI, -0.45 to 0.35) (Figure 7.1). 
Serum paraoxonase activity showed a large variability between subjects, with a range of 50.2-
340.5 U/L. The variability within-subjects was small: at a mean fasting serum paraoxonase 
activity of 130.1 U / L the SD within-subjects was 5.9 U/L , corresponding with a CV of 4.5% (25 
subjects, 2 fasting samples per subject). Serum paraoxonase activity was slightly higher 3.5h after 
the meals than fasting, with similar effects for both types of fat (Table 7.4). 
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Figure 7.1: 
Correlation between 
postprandial changes in 
triacylglycerols and 
flow-mediated 
vasodilation (FMO) in 
21 subjects after two 
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Discussion 
We found no difference in effect on postprandial flow-mediated vasodilation in 21 healthy men 
between high doses of trans fatty acids and saturated fatty acids. Thus, our previous observation 
that replacement of saturated fatty acids by trans fatty acids impaired flow-mediated vasodilation 
after 4 weeks could apparently not be explained by differences in acute effects of the fatty acids. 
Postprandial effects of fats on flow-mediated vasodilation 
We found a slight improvement from fasting values of flow-mediated vasodilation after the test 
meals. Although previous studies yielded conflicting results, most of them showed marked 
reductions in flow-mediated vasodilation after an oral fat load1315. Studies that showed an 
impairment of flow-mediated vasodilation by an oral fat load used similar doses of fat (0.9-1.0 
g/kg bodyweight) and study designs (measurements fasting and 3-4h postprandially) to ours 
(Table 7.1). We mixed the test fats with a milkshake, as was done by others14'16-17. The test meals 
were consumed under our supervision, and therefore non-compliance could not explain the 
unexpected outcome of the study. A difference with most other studies, however, is that our 
subjects were allowed to take either a 125 mL cup of coffee or tea (one choice throughout the 
whole study) with the test meals. If the corresponding dose of caffeine (60 mg for coffee and 40 
mg for tea18 had strong vasodilatory effects, up to 3 hours after consumption, this might have 
counteracted the effect of the test fats. However, we found no evidence for an effect of caffeine 
in the literature19'20. Thus, the fact that we did not find an impairment in flow-mediated 
vasodilation after a meal rich in either saturated or trans fat cannot be explained by differences in 
dose or study design. 
Flow-mediated vasodilation was not impaired by the test fats in our study, but was already 
quite low in our subjects: the fasting values were 2.6% of the resting diameter. This value is 
about half of that observed in our previous studies, but those studies were done in younger 
subjects, and flow-mediated vasodilation appears to decline with age21. Ong et al found a similar 
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value for lean, young, healthy men13, but most investigators reported higher values. Part of the 
higher values can be explained by the position of the cuff; because higher values for flow-
mediated vasodilation are found when the cuff is placed around the upper arm than around the 
lower arm, the position we used22. 
Correlation between changes in serum triacylglycerols and flow-mediated vasodilation 
In agreement with results of others17'23 we found that changes in serum triacylglycerols showed a 
negative correlation with changes in flow-mediated vasodilation, although statistically significant 
for saturated fatty acids only. This result appears to contradict our finding that flow-mediated 
vasodilation was slighdy higher 3h after the meals, when serum triacylglycerols were higher, than 
before the meals. Indeed, from Figure 7.1 it can be estimated that a zero change in serum 
triacylglycerols corresponded with an increase in flow-mediated vasodilation. This would suggest 
that flow-mediated vasodilation improves during the morning, because the first measurement 
was before 9:30am and the second was 3h later. Such a diurnal variation has been reported by 
others, with a change in flow-mediated vasodilation from 4.0% at 8:00am to 5.3% at 12:00noon 
in healthy young men24, although a different diurnal variation was found in women25. Maybe the 
increase in serum triacylglycerols in our study was too small to counteract such a diurnal 
variation in flow-mediated vasodilation; the increase 3.5h after the meals was moderate, with 
0.46 mmol/L after the Sat-meal and 0.68 mmol/L after the Trans-meal. However, many studies 
that did show an effect on flow-mediated vasodilation reported similar increases in serum 
triacylglycerols within the same time frame17'19'20'26. 
Long-term versus postprandial effects of trans fats and saturated fats 
We performed the present study to investigate whether trans fatty acids had acute effects on 
flow-mediated vasodilation besides the long-term adverse effects we had seen in our previous 
study (Chapter 3). Postprandial effects, however, were not different for saturated fatty acids and 
trans fatty acids. This is in agreement with the similar effects of trans fatty acids and saturated 
fatty acids on postprandial concentrations of serum triacylglycerols27'28, chylomicron 
triacylglycerols, serum HDL-cholesterol, the activity of cholesteryl ester transfer protein27, and 
Factor VII coagulant activity and activated Factor VII28. Moreover, we showed that postprandial 
changes in serum paraoxonase activity were not different between the two fats despite a 6% 
difference in fasting values after 4 weeks consumption of meals enriched with either of the two 
fats. Our hypothesis was that changes in paraoxonase activity would parallel changes in flow-
mediated vasodilation. This proved to be correct, but the changes in paraoxonase activity were 
probably too small to have caused the changes in flow-mediated vasodilation. Thus, postprandial 
differences between trans fatty acids and saturated fatty acids appear to be small or absent 
In conclusion, we found no impairment of flow-mediated vasodilation after test meals rich in 
either saturated or trans fatty acids. It is more likely that the impairment of flow-mediated 
vasodilation after 4 weeks consumption of a diet rich in trans fatty acids was mediated by a 
decrease in HDL-cholesterol. 
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Main conclusion from the studies in this thesis 
We investigated the difference in effect of trans fatty acids and saturated fatty acids on a marker 
of coronary heart disease risk. Our hypothesis was that the difference in HDL-cholesterol might 
be responsible for differences in risk of coronary heart disease; trans fatty acids reduce serum 
HDL-cholesterol, and low concentrations of HDL-cholesterol are related to high risk of 
coronary heart disease. We tested our hypothesis in diet studies using healthy volunteers. 
Endpoint of the studies was flow-mediated vasodilation, a marker of coronary heart disease risk. 
Our main conclusion from the studies in this thesis is: 
Replacement of saturated fatty acids in the diet by trans fatty acids reduces 
serum HDL-cholesterol and impairs f low-mediated vasodilation, which 
suggests an increased risk of cardiovascular disease. The evidence for a 
causal relation between changes in HDL-cholesterol and f low-mediated 
vasodilation, however, is inconsistent. 
This conclusion implies that we are uncertain whether the decrease in HDL-cholesterol is the 
mechanism behind the stronger relation with cardiovascular disease of trans fatty acids than of 
saturated fatty acids. 
We demonstrated, however, that replacement of saturated fatty acids by trans fatty acids 
impaired flow-mediated vasodilation. This supports the results of observational studies that 
intake of trans fatty acids relates more strongly to risk of cardiovascular disease than intake of 
saturated fatty acids. Moreover, this shows that adverse effects of trans fatty acids are not limited 
to serum lipoproteins, but extend to vascular reactivity. Our finding therefore supports the 
recommendation to limit the intake of trans fatty acids. 
Study limitations 
The effects of decreases in HDL-cholesterol on flow-mediated vasodilation were inconsistent. 
This is disturbing, because there are several indications that decreases in HDL-cholesterol do 
increase risk of coronary heart disease. Our results should therefore be examined against the 
background of strong evidence for a causal role of HDL-cholesterol in coronary heart disease: 
we might have missed an effect if flow-mediated vasodilation is not a valid risk marker. 
The results of the studies described in this thesis heavily depend on the validity of the use of 
flow-mediated vasodilation as an outcome in diet studies. In the following paragraphs the 
reproducibility and several technical aspects of the use of flow-mediated vasodilation will be 
discussed, because differences in technique may account for some of the discordant outcomes 
between studies. Some other techniques for the assessment of vascular reactivity will be 
discussed as well. After the discussion on technical aspects, a discussion on the possible 
mechanisms by which diet can affect vascular function will be given. Finally, suggestions for 
future studies will be made. 
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Reproducibility of flow-mediated vasodilation 
When we started this project, little was known about the variation in repeated measurements of 
flow-mediated vasodilation. Knowledge of this variation was crucial for choosing appropriate 
sample si2es for the diet studies, and therefore we started with the reproducibility study as 
described in Chapter 2. As turned out, the variation in repeated measurements of flow-mediated 
vasodilation was considerable. A large part of this variation could be explained by variation in 
the off-line analysis of the recorded images; the coefficient of variance for 13 measurements that 
were analysed twice was 30%. This analytical variation could be reduced by analysing all 
measurements two or more times and using the average of the analyses , as is done by some 
research groups13. 
Biological variation and variations in measurement performance can be reduced by repeated 
measurements per volunteer for each treatment The measurement site could be marked, but if 
measurements are several days apart this is not practical. We used the antecubital crease as a 
marker for our measurements, because this crease is easy to find and the artery is easy to locate 
at this site. Biological variation and variations in measurement performance can be further 
reduced by standardising the protocol as much as possible, as will be discussed below. 
Technical variations in the assessment of flow-mediated vasodilation 
In contrast to - for example - serum cholesterol concentrations, there is no consensus on 
'normal' values for flow-mediated vasodilation. Values that are considered to be an indication of 
coronary heart disease in one study may be considered normal in another. Some of the variation 
can be explained by differences in how flow-mediated vasodilation is measured. Although all 
non-invasive methods use high-resolution ultrasound to measure changes in the brachial artery 
diameter upon increased blood flow, several variations exist 
Position of the pneumatic cuff 
The cuff that is used for artery occlusion can be placed around the forearm (wrist) or upper 
arm. When placed around the forearm, it induces ischemia distal to the antecubital fossa; the site 
of measurement. When placed around the upper arm, it induces ischemia in the forearm 
(proximal to measurement site) plus the site of measurement, and a larger area of ischemia is 
likely to produce a larger increase in blood flow. However, some investigators argue that 
ischemia of the brachial artery itself, by upper arm occlusion, might lead to abnormal endothelial 
function and nitric oxide release4. For that reason we chose forearm occlusion in our studies. 
Several investigators compared the effect of the two cuff positions on flow-mediated 
vasodilation. Vogel et al found that placement of the cuff around the upper arm resulted in a 
larger blood flow and a larger flow-mediated vasodilation than placement of the cuff around the 
forearm (13.4±5.3% vs. 5.6±3.4% in 10 healthy subjects and 7.9±3.5% vs. 3.9±2.2% in 10 
subjects with one risk factor for coronary heart disease)5. This was later confirmed by 
investigators who found a flow-mediated vasodilation of 9.0±4.8% after upper arm and 
5.9+2.4% after lower arm occlusion in 16 subjects6. 
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They also found a larger increase in blood flow after release of the upper arm cuff (from 2.4±0.2 
to 33.1±3.1 mL/min per 100 mL) than after release of the lower arm cuff (from 2.5±0.5 to 
22.8+2.2 mL/min per 100 mL). Although a difference in flow-mediated vasodilation had not 
been found in earlier - smaller - studies with 6 subjects (upper arm cuff 4.8%±2.7% vs forearm 
cuff 5.4±4.8%)4 and 7 subjects (upper arm cuff 6.6±3.6% vs forearm cuff 8.3±4.9%)7, it appears 
that cuff position may explain some of the large variation in flow-mediated vasodilation between 
studies. 
Cuff pressure and occlusion time 
An occlusion time of 4.5-5 min and a cuff pressure of at least 50 mmHg suprasystolic are 
commonly used to measure flow-mediated vasodilation; we used 5 min of 230-250 mmHg. 
Several investigators have found that longer occlusion times hardly increase vasodilation; they do 
however increase discomfort to the volunteers4-8-9. An occlusion time of 1 or 3 minutes, 
however, is too short for maximal vasodilation in healthy volunteers4-7. 
Cuff pressure varies between studies, but is minimally 50 mmHg suprasystolic (»170 mmHg) 
and maximally 300 mmHg. We found no data on effects of graded cuff pressures on flow-
mediated vasodilation, but studies in which 300 mmHg was used do not seem to produce larger 
values of flow-mediated vasodilation than studies that used lower cuff pressures. 
Choice of 'maximum ' diameter 
Immediately after cuff release the brachial artery starts to dilate, to reach a maximum within 5 
min4-6-7. To calculate the percentage dilation, some investigators use the largest diameter that is 
reached; others use the diameter after 60 or 90 seconds. We used the largest diameter that was 
reached within 5 minutes after cuff-release, but in most of our volunteers this maximum was 
reached within 2 minutes. Others have shown that in healthy volunteers the maximum diameter 
is reached after approximately 1 min of cuff release4'6-8-10. In other words, the diameter 60 or 90 s 
after cuff release will be very close to the maximum diameter, and flow-mediated vasodilation 
will be similar. This difference in study protocols will therefore not result in large differences in 
the percentage flow-mediated vasodilation. 
Changes in resting (pre-occlusion) diameter in repeated measurements 
The percentage flow-mediated vasodilation is calculated as the percentage increase in 
diameter from the resting diameter. Differences between resting diameter before a meal and 
after a meal complicate the interpretation of changes in flow-mediated vasodilation. For 
example, in a study that compared pre- with post-prandial flow-mediated vasodilation, the 
resting diameter changed from 3.9±0.6 mm in the fasting subjects to 4.3+0.6 mm 2h 
postprandially. The corresponding maximum diameters were 4.2±0.6 and 4.6±0.6 mm, resulting 
in %flow-mediated vasodilation of 8% and 5.9%n . Thus, flow-mediated vasodilation was lower 
after the meals than before, but this may have been due to the smaller resting diameters before 
the meals. The same was found by other investigators12. 
82 
D I S C U S S I O N 
Wall-tracking versus B-mode ultrasound 
In our studies all recorded longitudinal images of the brachial artery were stored on super-
VHS videotapes for off-line analysis. Off-line analysis was done largely by hand: an observer 
marked the anterior and posterior walls over a length of at least 3 mm and a software program 
computed the average distance between the markings. This method is time-consuming and 
prone to substantial variation, as we showed in Chapter 2. However, it allows the observer to 
rate image quality and to detect possible movements of the arm. Another method is the wall-
tracking system; a wall movement detector system that detects and images radiofrequency signals 
from the vessel walls. From these signals, the distance at end-diastole is calculated for 4-5 cardiac 
cycles. The distance is calculated for one cross-section only (M-mode), as opposed to the 
longitudinal section of at least 3 mm in B-mode. The reproducibility of the wall-tracking system 
is hardly described in the literature; a coefficient of variation of 13.9% was reported for an 
unknown number of volunteers and repeated measurements13. 
Transducer frequency 
Ultrasound images are made with high-frequency emitting probes. Deeper structures are 
imaged with lower frequency probes than structures near the surface14. For example, 2 MHz 
probes are used for imaging the heart, and 13 MHz probes are used for imaging the carotid or 
brachial artery. For imaging of the brachial artery probes ranging from 7.5-14 MHz are 
commonly used. The probe frequency affects the axial resolution; the ability to resolve objects 
that lie one above the other. Although the axial resolution of images will be better when a higher 
frequency probe is used (resolution or wavelength equals velocity divided by frequency), the 
resolution also depends on other factors, such as the resolution of the monitor and the scan 
depth. In theory, a 14 MHz probe will yield a resolution of 0.11 mm (using an ultrasound 
velocity of 1540 m/s in soft tissue). 
Measurement arm 
When flow-mediated vasodilation is measured repeatedly, it is always measured at the same 
side of a subject or patient; either at the left or the right arm. Earlier studies have shown that 
blood flow response after ischemia is higher in the dominant arm than in the non-dominant 
arm15'16. It therefore makes sense to choose either the dominant or the non-dominant arm in 
studies that compare flow-mediated vasodilation between groups. In our studies flow-mediated 
vasodilation was compared within subjects, and it is unlikely that changes in flow-mediated 
vasodilation are different between arms. Therefore we did all measurements at the right arm, 
which was more practical than switching from right to left arm if a subject was left-handed. 
Moreover, left-handedness in adults has been shown to be less than 10% in English and 
German population samples17'18, which is probably not much different from the frequency in 
dutch adults. Thus, the majority of our measurements was done at the dominant (right) arm. 
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Fasting or fed subjects: circadian rhythm and meal effects 
There are some reports on a possible circadian rhythm in flow-mediated vasodilation, but 
whether this is due to being in a fasting or fed state or to other factors is unknown. For example, 
flow-mediated vasodilation in healthy young men was 4.0% at 8:00am, 5.3% at 12:00noon, 9.7% 
at 5:00pm, and 6.9% at 9:00pm19. A different diurnal variation of flow-mediated vasodilation 
was found in 16 young women: 3.9% at 8:00h, 3.1% at 2:00pm, 4.4% at 8:00pm, and a peak of 
5.1% at 2:00am20. These women consumed a nitrate/nitrite-poor diet during the study periods, 
and retrained from drinking caffeine-containing beverages. The times, amounts, and 
compositions of the meals, however, were not controlled, and these might have increased the 
variation in flow-mediated vasodilation during the day in both studies. Thus, it is unclear to what 
extent this circadian rhythm interferes with study protocols. 
Other measures of vascular structure and reactivity 
Flow-mediated vasodilation is not the only method for measuring vascular reactivity that is used 
as an intermediary outcome in clinical and diet studies. Other measures - including measures of 
vascular structure - are intima media thickness, venous plethysmography, and several measures 
of systemic or coronary arterial compliance. The similarities and differences with flow-mediated 
vasodilation will be discussed in the following paragraphs. 
Intima media thickness (IMT) is a measure of vascular wall thickness, and is commonly 
measured in the carotid artery, where it can be measured with external ultrasound21. IMT of the 
carotid artery increases with age, by 3-lOp.m/y10'22. IMT is positively associated with coronary 
events23 and stroke24. Several studies have shown that flow-mediated vasodilation is smaller 
when intima media thickness is larger25'26. This may be due to increased stiffness of the carotid 
arteries, because the response to a sublingual dose of nitroglycerin was also less with increased 
intima media thickness26. We did not choose IMT as and endpoint for our studies because of the 
large number of subjects needed for an adequate sample size and the long duration of follow-up. 
Forearm plethysmography is another technique for measuring flow-mediated vasodilation, 
based on the same principle that an increase in blood flow triggers nitric oxide release. 
Plethysmography does not use ultrasound but uses special sensors that detect swelling of the 
forearm27. Because the principle of the two techniques is the same, flow-mediated vasodilation 
as assessed by forearm plethysmography is likely to respond similarly to food or drug treatment 
as flow-mediated vasodilation assessed by ultrasound. Statin treatment, for example, was shown 
to improve flow-mediated vasodilation measured by venous occlusion plethysmography28 and 
by high-resolution ultrasound29. 
Several non-invasive techniques have been developed to measure arterial stiffness, which is 
the reciprocal of arterial distensibility or arterial compliance. These techniques all depend on 
meaurements of changes in blood flow, volume, or vessel area induced by differences in blood 
pressure from end systole to end diastole. like flow-mediated vasodilation, arterial compliance 
decreases with age10-30. Arterial compliance can be improved, as was shown after 
supplementation with flaxseed oil31 and soy isoflavones32. Changes in arterial 
compliance/distensibility do not need to imply changes in flow-mediated vasodilation: soy 
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isoflavone supplementation improved systemic arterial compliance in 9 women, but did not 
improve acetylcholine-mediated vasodilation32. Moreover, no correlation was found between 
arterial compliance and flow-mediated vasodilation in 50 healthy men and women (r=0A0, 
P>0.05)10. We did not choose any of the compliance measurements as an endpoint, because 
flow-mediated vasodilation appeared to be better correlated with known risk factors for 
coronary heart disease. 
In conclusion, flow-mediated vasodilation as assessed by ultrasound is likely to yield the same 
results as when assessed by venous occlusion plethysmography. Changes in flow-mediated 
vasodilation not necessarily need to imply changes in intirna media thickness or arterial 
compliance. The measurement of flow-mediated vasodilation is prone to a high variation; 
standardisation of the technique is crucial. 
Diet, lipids and flow-mediated vasodilation 
Dietary modulation of endothelial function is regarded as a means to preventing cardiovascular 
disease33. Flow-mediated vasodilation is one of several assessments of endothelial function; it 
depends on nitric oxide release by the endothelial cells34'35. It is thought that effects on flow-
mediated vasodilation are mediated through changes in the bioavailability of nitric oxide. As a 
consequence, many studies have looked at the role of antioxidant vitamins or oxidised 
lipoproteins33-36'37. 
It is unlikely that antioxidant vitamins played a role in our studies, because any difference in 
vitamin content between the diets used in our studies would have been too small to elicit an 
effect Oxidisability of lipoproteins might have played a role, but we did not include markers of 
oxidative stress in our studies38, so any discussion on this topic would be mere speculation. The 
discussion will therefore be limited to what is known about HDL-cholesterol, paraoxonase, and 
acute effects of fatty meals on vascular function. 
Serum HDL-cholesterol and vascular function 
HDL-cholesterol is positively related to flow-mediated vasodilation in some cross-sectional 
studies3M3. However, effects of changes in HDL-cholesterol on vascular reactivity have hardly 
been studied; they are limited to a drug trial. In this trial, 100 patients with low initial HDL-
cholesterol (<1 mmol/L) but normal LDL-cholesterol (<4 mmol/L) were randomised to 
treatment with gemfibrozil and niacin or cholestyramin. The aim was to increase HDL-
cholesterol by at least 25% and to lower LDL-cholesterol to <2.8 mmol/L. Although serum 
lipoprotein concentrations significantly improved in the treatment group - HDL-cholesterol 
increased by 0.25 mmol/L and LDL-cholesterol decreased by 0.8 mmol/L - flow-mediated 
vasodilation did not change44. Statin therapy, on the other hand, improved vascular reactivity, 
but hardly increased serum HDL-cholesterol in the same studies28'45. Thus, effects of changes in 
HDL-cholesterol on vascular function, as assessed by flow-mediated vasodilation, are 
inconsistent. 
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Paraoxonase and vascular function 
Paraoxonase is a component of HDL. It has been shown to inhibit copper-catalysed oxidation 
of LDL in vitro46. If such an inhibition also occurs in vivo, this might have an effect on vascular 
function, because oxidised LDL is thought to reduce nitric oxide production and 
bioavailability47. Indeed, there are suggestions that LDL isolated from serum of subjects with 
low paraoxonase activity is more susceptible to oxidation than LDL from subjects with high 
serum paraoxonase activity48-49. This could lead to differences in vascular reactivity, because 
oxidised LDL has many in vitro effects that might affect vascular reactivity in vivo37. However, 
paraoxonase is not the only enzyme involved in the formation of oxidised LDL50-51. This may be 
one of the reasons that relations between paraoxonase activity and coronary heart disease are 
complex and inconsistent 
We found only minimal differences in serum paraoxonase activity induced by the diets in our 
studies. Whether these differences had an effect on flow-mediated vasodilation remains 
unknown; no other data on paraoxonase activity and vascular function were found in the 
literature. 
Acute effects of high-fat meals 
Several studies have found that dietary lipids decrease flow-mediated vasodilation, as is reviewed 
in the introduction of Chapter 7. The mechanism for this effect is not yet understood52, and 
finding the mechanism is complicated by studies that reported no change in flow-mediated 
vasodilation after oral fat loads, such as our own study. In one such study, only fat that had been 
used for deep-fat frying caused an impairment of flow-mediated vasodilation53. This suggests 
that not the triacylglycerols, but rather their breakdown products are responsible for the 
impairment of flow-mediated vasodilation52. In contrast to that result, infusion of triacylglycerols 
decreased flow-mediated vasodilation within 1 h in 7 healthy volunteers. However, no control 
infusion was included to check whether infusion of fluids had an effect on flow-mediated 
vasodilation54. In summary, this research area has produced inconsistent results. Furthermore, it 
is unclear whether a disturbed flow-mediated vasodilation after an oral fat load is predictive of 
future cardiovascular disease. 
Suggestions for future studies 
Predictive value of flow-mediated vasodilation measurements 
Flow-mediated vasodilation is widely used as an endpoint in clinical and diet studies. However, 
hard data on the value of flow-mediated vasodilation as a predictor of future coronary heart 
disease is lacking. At present there is no consensus on a 'normal' value for flow-mediated 
vasodilation; thus, it is unclear which treatment effects are physiologically relevant Large cohort 
studies that relate flow-mediated vasodilation at present with future coronary heart disease could 
provide these data. 
86 
D I S C U S S I O N 
Effects of fats on vascular reactivity 
Acute effects of high doses of fat on vascular reactivity have been inconsistent Future studies 
should use stricter test meals, differing only in fat content or fatty acid composition. Dose 
response studies might help understand the importance of dietary fat on vascular function52. 
There is no data on the predictive value of an impaired postprandial vascular reactivity. Thus, 
we do not know whether it predicts the risk of future coronary heart disease. To resolve this, 
cohort studies that are designed to relate fasting flow-mediated vasodilation with disease could 
include measurements of flow-mediated vasodilation after standardised meals. 
Trans fatty acids 
Most of what we know about trans fatty acids is based on research with elaidic acid; there is little 
data on other isomers. Experimental diet studies with specific trans fatty acids may ascertain 
whether the deleterious effects hold for all trans fatty acids or only a subset This could also 
resolve whether trans fatty acids of animal origin, e.g. vaccenic acid, have the same effects as 
elaidic acid. 
Experimental studies with trans fatty acids have used doses far outside the range of ordinary 
intake. Epidemiological studies suggest that different populations have remarkable differences in 
trans fatty acids intake, and that adverse effects might be restricted to those populations with a 
high intake. Dose-response studies could provide data in which amounts of trans fatty acids can 
be correlated with changes in serum lipoproteins and thus in risk. 
The mechanism by which trans fatty acids increase serum LDL-cholesterol and decrease 
HDL-cholesterol are not fully understood. Mechanistic studies, as have been done for e.g. 
cafestol and kawheoL, the cholesterol-raising lipids in coffee, would provide insight in this 
mechanism. 
Could trans fatty acids be replaced? Many tropical fats, rich in saturated fats, are solid at room 
temperature. They can add firmness and texture to foods just like trans fats. Intake of saturated 
fats as a whole is related to cardiovascular disease, but whether this holds for the separate fatty 
acids, e.g. for palmitic and lauric acids, remains to be resolved. Different fatty acids have 
different effects on serum lipoproteins and thrombosis tendency; it is likely that they have 
different effects on disease risk. Further comparison of individual saturated fatty acids in 
experimental diet studies might help find out which fats could be a prudent replacement of trans 
fats. 
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Summary 
Aim of the studies in this thesis 
Consumption of trans fatty acids increases risk of cardiovascular disease; presumably by 25% for 
each additional 2% of energy from these fatty acids. This increase in risk is stronger than that of 
saturated fatty acids, despite similar effects on DDL-cholesterol. We investigated whether the 
decrease in HDL-cholesterol could explain the additional risk of cardiovascular disease with 
consumption of trans fatty acids. We used flow-mediated vasodilation, a marker of 
cardiovascular disease risk, as principal outcome of our studies. Flow-mediated vasodilation is 
the percentage increase in the diameter of an artery after a provoked local increase in blood flow. 
An impaired flow-mediated vasodilation appears to predict future coronary events. In all studies 
in this thesis flow-mediated vasodilation was measured non-invasively with high-resolution 
ultrasound in the brachial artery. 
Reproducibility and sample size (Chapter 2) 
In a pilot study with 13 volunteers measured 6 times each we found a mean flow-mediated 
vasodilation of 5.6% of the baseline diameter. The within-subject standard deviation was 2.8 
percentage points, so the corresponding coefficient of variation was 50%. From these data we 
estimated that we would need 32 volunteers in future cross-over designs to detect a treatment 
effect of 2 percentage points with 5% probability and a power of 80%. 
The TransSat-study (Chapters 3, 5, and 6) 
The TransSat-study was a dietary controlled study with 32 men and women in a cross-over 
design with two diets. The aim of this study was to decrease serum HDL-cholesterol with trans 
fatty acids and to measure the effect on flow-mediated vasodilation. The Trans-diet provided 
9.2% of energy from trans fatty acids, these were replaced by saturated fatty acids in the Sat-diet. 
After 4 weeks, serum HDL-cholesterol was 1.87 mmol/L after the Sat-diet and 1.48 mmol/L 
after the Trans-diet, a difference (95% CI) of 0.39 (0.28 to 0.50) mmol/L. The low HDL-
cholesterol was parallelled by an impaired flow-mediated vasodilation, which was 4.4% after the 
Trans-diet; significantly lower than the 6.2% after the Sat-diet with a difference of 1.8%-points 
(0.4, 3.2). This result suggested that decreases in HDL-cholesterol impair flow-mediated 
vasodilation, and thereby increase risk of cardiovascular disease. However, this finding had to be 
confirmed. 
The CarbOil-study (Chapter 4) 
We sought confirmation for the impairment of flow-mediated vasodilation after a decrease in 
HDL-cholesterol in a subsequent cross-over study in which we lowered serum HDL-cholesterol 
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by replacement of monounsaturated fat by carbohydrates. Although serum HDL-cholesterol 
was lowered by 0.21 (0.17, 0.26) mmol/L, flow-mediated vasodilation was not impaired. Instead, 
flow-mediated vasodilation was 4.1% after the diet rich in monounsaturated fat and 4.8% after 
the diet rich in carbohydrates, a difference of 0.7%-points (-0.6, 1.9). We checked whether the 
carbohydrate-rich diet, with its 124g larger fruit and 80g larger vegetable content, had reduced 
serum homocysteine, which may have improved flow-mediated vasodilation, but this was not 
the case. Thus, either the decrease in serum HDL-cholesterol had been too small to elicit an 
effect, or HDL-cholesterol was not causally related to flow-mediated vasodilation. In that case, 
the effect of trans fatty acids on flow-mediated vasodilation may have been mediated by other 
factors, such as serum paraoxonase activity. 
Serum paraoxonase activity (Chapter 6) 
We decided to measure serum paraoxonase activity in serum samples of the TransSat- study. 
Paraoxonase is an HDL-bound enzyme that can hydrolyse oxidised lipids in LDL and HDL 
particles; and oxidised lipids may impair endothelial function as suggested by in vitro and animal 
studies. Moreover, serum paraoxonase activity is inversely related to risk of coronary heart 
disease in cross-sectional studies, and to vasoreactivity in patients with coronary heart disease. 
We found that serum paraoxonase activity was 196umol/L/min after the Sat-diet and 6% (2%, 
10%) lower, or 185umol/L/min, after the Trans-diet. This difference is about half that between 
smokers and non-smokers, who also differ markedly in flow-mediated vasodilation. Thus, 
consumption of trans fatty acids for 4 weeks not only reduced serum HDL-cholesterol but also 
reduced the activity of serum paraoxonase. Whether this contributed to the impairment of flow-
mediated vasodilation, however, remains to be determined. The last question we wished to 
answer was whether replacement of saturated fat by trans fat could impair flow-mediated 
vasodilation independent of changes in HDL-cholesterol. We did this by comparing 
postprandial effects of the two fats on flow-mediated vasodilation. 
The Before&After-study (Chapter 7) 
Based on reports by others we hypothesised that meals rich in saturated or trans fat would impair 
postprandial flow-mediated vasodilation, and based on the TransSat study we expected to see a 
larger effect with trans fat Twenty-five men were given oral fat loads (0.9-1.0 g fat/kg 
bodyweight) with saturated or trans fatty acids, and flow-mediated vasodilation was measured 
before and 3 h after the fat load. In contrast to reports by others we found a vasodilation of 
3.1% after the meals, which was higher than the 2.6% before the meals. Moreover, we found no 
differences in change in flow-mediated vasodilation between the two types of fat. 
Serum paraoxonase activity parallelled the change in flow-mediated vasodilation, and was 
about 2% higher after the meals than before. In accordance with reports by others we found 
that postprandial changes in serum triacylglycerols were inversely related with changes in 
flow-mediated vasodilation. 
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Conclusion 
In conclusion, we found that replacement of dietary saturated fatty acids by trans fatty acids for 
several weeks impaired flow-mediated vasodilation, a marker of cardiovascular disease risk. This 
effect may have been caused by the concomitant decrease in serum HDL-cholesterol, but this 
was not confirmed in our second diet study in which we decreased HDL-cholesterol by a low-
fat diet The effects of trans fatty acids on flow-mediated vasodilation appeared to be long-term 
only: single meals rich in trans fatty acids or saturated fatty acids did not act differently on 
postprandial flow-mediated vasodilation. Serum paraoxonase activity parallelled changes in flow-
mediated vasodilation in both studies with trans fatty acids, but whether this is causal remains to 
be determined. Thus, evidence for a causal role of HDL-cholesterol in coronary heart disease 
remains convincing but tentative. 
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Samenvatting 
De2e Nederlandse samenvatting is bedoeld voor de geinteresseerde leek. Een meer beknopte 
samenvatting voor wetenschappers wordt gegeven in de Summary. 
Wat was het doel van het onderzoek? 
Dit proefschrift draait om de vraag waarom consumptie van toww-onverzadigd vet gepaard gaat 
met een hogere kans op het krijgen van hart- en vaatziekten dan consumptie van verzadigd vet 
Tra/w-onverzadigd vet, vanaf hier aangeduid met transvet, vormt 2-5 procent van het vet in de 
Nederlandse voeding. Fast foods, snacks, koekjes en crackers zijn belangrijke bronnen van 
transvet in een westerse voeding. Consumptie van transvet verhoogt het gehalte aan LDL-
cholesterol in het bloed, net als consumptie van verzadigd vet, en dit is een ongunstig effect 
Bovendien verlaagt consumptie van transvet het gehalte aan HDL-cholesterol, een effect dat niet 
optreedt bij consumptie van verzadigd vet We hebben onderzocht of deze verlaging van het 
HDL-cholesterolgehalte bijdraagt aan de verhoging van de kans op hart- en vaatziekten door 
consumptie van transvet 
Wat was de hypothese? 
Onze hypothese was dat transvetzuren de kans op het ontstaan van hart- en vaatziekten meer 
verhogen dan verzadigd vet omdat ze het gehalte aan HDL-cholesterol in het bloed verlagen. 
Uit grote bevolkingsstudies is bekend dat een laag gehalte aan HDL-cholesterol in het bloed 
meer voorkomt bij personen met hart- en vaatziekten dan bij gezonde personen. Dit is 
tegengesteld aan de relatie tussen het LDL-cholesterolgehalte en hart- en vaatziekten, want 
hiervoor geldt juist dat een hoog gehalte vaker voorkomt bij personen met hart- en vaatziekten. 
Het is bekend dat een verlaging van het LDL-cholesterolgehalte in het bloed met medicijnen of 
een dieet de kans op hart- en vaatziekten verlaagt Het is echter nog onbekend of een verhoging 
van het gehalte aan HDL-cholesterol hetzelfde effect heeft 
Hoe werd de kans op hart- en vaatziekten onderzocht? 
Om nu te onderzoeken of /ra«jvetzuren de kans op het ontstaan van hart- en vaatziekten 
verhogen door verlaging van het HDL-cholesterolgehalte hebben we een aantal 
voedingsexperimenten gedaan. De voedingsexperimenten duurden maximaal 8 weken. 
Daardoor was het onmogelijk om te onderzoeken of de proefpersonen meer of minder hart- en 
vaatziekten kregen; dit is immers een proces dat jaren duurt In plaats daarvan hebben we een 
surrogaat eindpunt gekozen in de vorm van vaatwandfunctie. Vaatwandfunctie kan worden 
gedefinieerd als de mate van verwijding van een bloedvat als gevolg van een verhoogde 
bloeddoorsttoming door dat vat. 
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O m de vaatwandfunctie te bepalen hebben we bij proefpersonen de diameter van de 
armslagader gemeten voor- en nadat de bloeddoorstroming experimented werd verhoogd. Het 
meten van de diameter gebeurt met ultra-geluidsgolven Cechogolven1); er wordt een echo 
gemaakt van de armslagader ter hoogte van de elleboogplooi. Vervolgens wordt de 
bloeddoorstroming experimented verhoogd: een bloeddrukband wordt om de onderarm 
aangebracht, opgeblazen tot de armslagader wordt afgesloten, en vervolgens, na 5 minuten, weer 
leeggelaten. Als reactie op de toegenomen doorstroming van de armslagader neemt de diameter 
toe, en bereikt een maximum binnen 5 minuten. Uit de maximale diameter en de 
aanvangsdiameter wordt het percentage verwijding berekend; dit is de FMD die in dit 
proefschrift centraal staat FMD staat voor flow-mediated vasodilation, ofwel vaatverwijding door 
toegenomen doorstroming. 
Het is bekend dat patienten met hart- en vaatziekten een slechtere vaatwandfunctie en dus 
een lagere FMD hebben dan gezonde mensen. Bovendien lijkt het erop dat een slechte 
vaatwandfunctie voorspellend is voor het optreden van hart- en vaatziekten. Ook is bekend dat 
vrijwel alle bekende risicofactoren voor hart- en vaatziekten samengaan met vaatwandfunctie. 
Een hoog serum cholesterolgehalte, roken, en suikerziekte gaan bijvoorbeeld allemaal samen 
met een verlaagde FMD. Tevens is bekend dat veranderingen in die risicofactoren naar meer 
gunstige waarden, bijvoorbeeld een verlaging van het cholesterolgehalte, een verbetering van de 
vaatwandfunctie tot gevolg hebben. Dit was voor ons voldoende reden om te onderzoeken hoe 
transvet de vaatwandfunctie beinvloedt Een effect op de FMD zou immers aanwijzingen geven 
over het effect op de kans op het ontstaan van hart- en vaatziekten. 
Welke onderzoeken zijn uitgevoerd? 
We zijn begonnen met een schatting te maken van de dag-tot-dag variatie in vaatwandfunctie 
(Hoofdstuk 2). Het is nodig om die variatie te weten, want hoe groter de variatie, dus hoe meer 
schommding in vaatwandfunctie, hoe meer proefpersonen er nodig zijn om veranderingen in 
vaatwandfunctie aan te tonen. O m de variatie te schatten hebben we bij 13 proefpersonen de 
vaatwandfunctie 6 maal gemeten. Uit die metingen konden we afleiden dat de gemiddelde FMD 
0.225 mm was, ofwel 5.6% van de aanvangsdiameter, en dat de dag-tot-dag variatie binnen een 
proefpersoon 2.8% (0.115 mm) was, dus de helft van de gemiddelde FMD. Hieruit konden we 
berekenen dat we 32 proefpersonen nodig hadden als we een verschil van 2 F M D % als werkelijk 
verschil en niet als toeval wilden kwalificeren. 
De TransSat-proef 
In de eerste voedingsproef vergeleken we het effect op vaatwandfunctie van een voeding rijk aan 
transvetzuren met een voeding rijk aan verzadigde vetzuren (Hoofdstuk 3). O m die vergelijking 
zo zuiver mogelijk te houden werd de gehele dagvoeding aan de proefpersonen verstrekt; zowel 
warm eten als broodmaaltijden en tussendoortjes. De proefpersonen kregen eerst 4 weken de 
ene voeding te eten, daama 4 weken de andere voeding. Het gehalte aan HDL-cholesterol in het 
serum was aanzienlijk verschillend aan het eind van de twee voedingen: 1.87 mmol/L na de 
voeding rijk aan verzadigde vetzuren en 1.48 mmol/L na de voeding rijk aan transvetzuren 
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(Hoofdstuk 5). Het gehalte aan LDL-cholesterol bleef constant Onze verwachting was dat een 
verlaging van HDL-cholesterol door transvetzuren de vaatwandfunctie zou verminderen, en dat 
klopte: de FMD was 6.2% na de voeding rijk aan verzadigde vetzuren en 4.4% na de voeding 
rijk aan transvetzuren. Hoewel nu zichtbaar was gemaakt dat transvetzuren inderdaad een 
sterker effect op de kans op hart- en vaatziekten hadden dan verzadigde vetzuren, hadden we 
nog geen bewijs dat dat verschil in risico het gevolg was van het verschil in HDL-cholesterol. In 
de CarbOlie-proef probeerden we dat bewijs te leveren. 
De CarbOlie-proef 
We onderzochten of een tweede verandering in HDL-cholesterol, bij een nieuwe groep van 
proefpersonen en met andere voedingen, eveneens voor een verschil in vaatwandfunctie zou 
zorgen (Hoofdstuk 4). De twee voedingen die nu werden vergeleken waren een voeding rijk aan 
enkelvoudig verzadigde vetzuren (voornamelijk uit olijfolie) en een voeding die arm was aan 
vetzuren maar rijk aan koolhydraten. Net als in de eerste voedingsproef werd al de gehele 
dagvoeding weer verstrekt aan de proefpersonen. Zoals verwacht daalde het HDL-gehalte 
wanneer de voeding rijk aan koolhydraten werd gegeten; een daling van 1.66 naar 1.44 mmol/L. 
De vaatwandfunctie nam echter niet af, maar nam zelfs iets toe, van 4 .1% naar 4.8%, hoewel dat 
waarschijnlijk toeval was. We konden dus niet bevestigen dat een daling van het HDL-
cholesterol een vermindering van de vaatwandfunctie tot gevolg had. 
Serum paraoxonase 
Vervolgens hebben we geprobeerd het effect van transvetzuren op de vaatwandfunctie te 
verklaren uit activiteitsmetingen van het enzym paraoxonase, een enzym dat betrokken lijkt te 
zijn bij de antioxidantwerking van HDL (Hoofdstuk 6). Een lage activiteit van dit enzym wordt 
gezien bij patienten met hart- en vaatziekten en bij rokers. De voeding rijk aan transvetzuren 
bleek niet alleen de concentratie aan HDL-cholesterol in het bloed te verlagen, maar ook de 
activiteit van het paraoxonase te verminderen, en dit lijkt een ongunstig effect. Het zou kunnen 
betekenen dat HDL een lagere antioxidantwerking had tijdens consumptie van transvetzuren. 
Mogelijk had dit een ongunstig effect op vaatwandfunctie, maar dit is nog onvoldoende 
uitgezocht. Het is ook mogelijk dat de activiteit van serum paraoxonase een maat was voor de 
hoeveelheid HDL in serum, en geen causale rol speelde. 
De Voor&Na-studie 
Ter afsluiting leek het ons verstandig te onderzoeken of een eenmalige hoge dosis van 
transvetzuren de vaatwandfunctie kon verminderen, onafhankelijk van veranderingen in HDL-
cholesterol (Hoofdstuk 7). Voor deze proef moesten de proefpersonen op 4 meetdagen nuchter 
blijven en kregen ze van ons een milkshake waaraan 60-90 gram vet was toegevoegd. Tweemaal 
kregen ze een milkshake rijk aan verzadigde vetzuren en tweemaal een milkshake rijk aan 
transvetzuren, en we bepaalden hun vaatwandfunctie voordat en 3 uur nadat ze de milkshake 
hadden gedronken. Het bleek dat hun vaatwandfunctie na de milkshake iets beter was dan 
ervoor, een effect wat tegengesteld was aan wat andere onderzoekers hadden gevonden. 
Bovendien was er geen verschil in effect tussen transvetzuren en verzadigde vetzuren. Hoewel 
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vervanging van verzadigd vet in de voeding door transvet in de TransSat-studie leidde tot een 
vermindering van vaatwandfunctie, was dit dus niet het geval na een enkele maaltijd met deze 
vetten. 
Welke consequenties hebben de resultaten van de onderzoeken? 
We hebben niet kunnen aantonen dat transvetzuren de kans op hart- en vaatziekten meer 
verhogen dan verzadigde vetzuren omdat ze het HDL-cholesterolgehalte verlagen. We hebben 
echter wel kunnen aantonen dat een hoge consumptie van transvetzuren gedurende enkele 
weken nadelige effecten heeft op de vaatwandfunctie. Een verminderde vaatwandfunctie leidt 
op lange termijn mogelijk tot hart- en vaatziekten, hoewel dit nog niet onomstotelijk bewezen is. 
Onze resultaten ondersteunen het advies om zo min mogelijk producten rijk aan transvetten te 
consumeren. Dit betekent vooral een beperkte consumptie van snacks, koekjes en fast foods, de 
belangrijkste leveranciers van transvetzuren in de westerse voeding. 
96 
97 
D A N K W O O R D 
Dankwoord 
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Vaatwandfunctie was nog niet eerder gemeten op de afdeling dus moest er iemand worden 
gevonden die zich de metingen eigen kon maken. Jan Harryvan heeft dat uitstekend gedaan. Met 
zijn enorme geduld, nauwgezetheid en technisch inzicht verkreeg hij in korte tijd het certificaat 
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onderzoeksdietiste Saskia Meyboom. Ze kon daarvoor deels teruggrijpen op beproefde 
receptuur, maar had toch nog heel wat rekenwerk aan de proef. En niet zonder resultaat de 
door Saskia berekende voedingen kwamen precies overeen met de chemische analyses door 
Truus Kosmeyer van het lab. Bij de twee laatste voedingsproeven lag de verantwoordelijkheid 
voor het rekenwerk en 'de keuken' bij Els Siebelink: zij rustte niet voor de ideale samenstelling 
uit de printer rolde. Haar praktische blik op onderzoeksvoorstellen en haar strakke hand in de 
keuken namen mij heel wat zorgen uit handen. Ik ben dan ook blij dat ze me naast Liesbeth 
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rapporteren wil ik hartelijk bedanken. Ook het FACIT-team, dat bijsprong bij gebrek aan ruimte 
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